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1. INTRODUCTION 
Schizophrenia is a severe psychiatric disorder that has a strong biological basis 
and is characterized by significant impairments in reality testing, behaviour and 
functioning.   
Enormous efforts have been made to understand the brain functioning that is 
related to schizophrenia at the molecular, cellular, and system level. Arguably, 
however, these advances in neuroscience have been slow in translating into 
clinical practice (Insel 2010). One considerable problem here may be the nature 
of psychiatric disease entities themselves. Since its designation as dementia 
preacox by Emil Kraepelin (Kraepelin 1896) and schizophrenia by Eugen 
Bleuler (Bleuler 1911), schizophrenia has been defined by an account of 
symptoms that are obtained from the patient during clinical interview or by 
observation, combined with certain inclusion and exclusion criteria regarding 
the course of the illness and impairment of functioning. Although the diagnoses 
are reliable, the disease has no unified biological parameters that define its 
diagnosis (Kapur et al. 2012). This means that biological validity of the 
clinically observed phenotype is low.  
To broaden the understanding of psychiatric disorders, Kendler et al. (2011) 
have put forward the mechanistic property cluster model. In this view mental 
disorders can be represented as multi-dimensional matrices that reflect various 
attributes of human mind/brain such as genes, neural systems, physiological 
states, particular symptoms and environmental contributions. This model suggests 
that there are robust explanatory structures to be discovered underlying most 
psychiatric disorders, but these structures are multifaceted and complicated: no 
psychiatric disease has a singular cause (Kendler et al. 2011). Finding a solution 
to these yet incompletely characterized processes that underlie the psychiatric 
disorders, and particularly the cluster of clinical symptoms collectively referred 
to as schizophrenia is a great challenge for neuroscientists. 
Among other things, neurobiological differences in widely-acting neuro-
transmitter systems, subtle changes in brain microstructure, and neuronal net-
work connectivity give rise to a variety of affective, psychotic, and cognitive 
symptoms seen in schizophrenia (Schaefer et al. 2013).  
Mounting evidence suggests that compromised cognitive function is a 
central feature of schizophrenia (Gold & Harvey 1993; Heinrichs & Zakzanis 
1998). There is a frequently occurring and characteristic pattern of cognitive 
deficits, which is relatively stable over time and somewhat independent of the 
other manifestations of the psychotic symptoms. Among the most striking 
aspects of the cognitive profile of individuals with schizophrenia is that, at the 
group level, no cognitive function operates comparably to age- and gender-
matched healthy control subjects. It has therefore been suggested that cognitive 
performance is a powerful predictor, correlate or perhaps even a causal 
determinant of the impaired functionality in schizophrenia patients (Harvey 
2013).  
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Schizophrenia is certainly a longitudinal concept, and in order to reach a 
better understanding of its neurobiological basis, attempts need to focus on the 
different phases of the illness, distinguishing its prodromal, first- and multiple-
episode phases. In the field of psychiatric research, there is growing interest in 
the early stage of the psychosis.  
Investigating clinical manifestations, particularly cognitive performance in 
patients at the early stages of the illness, has the advantage of identifying cogni-
tive deficits more likely to reflect the neurodysfunction that underlies schizo-
phrenia rather than possible disease or treatment related processes following the 
chronic course of the illness.  
The overall aim of the research presented within this thesis was to investi-
gate cognitive functioning of the first-episode psychosis/schizophrenia patients 
using Cambridge Neuropsychological Test Automated Battery (CANTAB), and 
to study its relationships with clinical, demographic and brain morphological 
parameters.  
The work reported herein will enhance our understanding about the cogni-
tive deficits as a characteristic feature of the first episode psychosis patients and 
expand the existing knowledge in this field.   
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2. REVIEW OF LITERATURE 
2.1.  Definitions and diagnosis 
Psychosis is a syndrome – a mixed set of symptoms that characterize how a 
person's mental capacity, affective response, and capacity to recognize reality, 
communicate, and relate to others is impaired (Stahl 2013). Psychotic disorders 
are neuropsychiatric illnesses and the most common of them is schizophrenia. 
The ICD-10 (10th revision of the International Statistical Classification of 
Diseases) diagnostic criteria for schizophrenia are summarized in Table 1. In 
addition, to meeting these criteria, an individual must have experienced perva-
sive disturbance of social or vocational functioning resulting from the 
symptoms.  
 
 
Table 1. Summary of the ICD-10 general diagnostic criteria for schizophrenia. 
A diagnosis of schizophrenia is satisfied whereas either at least one of the syndromes, 
symptoms and signs listed below under (1), or at least two of the symptoms and signs 
listed under (2), should be present for most of the time during an episode of psychotic 
illness lasting for at least one month (or at some time during most of the days). 
(1) At least one of the following: 
 a) Thought echo, thought insertion or withdrawal, or thought broadcasting. 
 b) Delusions of control, influence or passivity, clearly referred to body or 
limb movements or specific thoughts, actions, or sensations; delusional 
perception. 
 c) Hallucinatory voices giving a running commentary on the patient's 
behaviour, or discussing him between themselves, or other types of 
hallucinatory voices.  
 d) Persistent delusions of other kinds that are culturally inappropriate and 
completely impossible.  
(2) Or at least two of the following: 
 e) Persistent hallucinations in any modality, when accompanied by 
delusions, without clear affective content, or when accompanied by 
persistent over-valued ideas. 
 f) Incoherent or irrelevant speech. 
 g) Catatonic behaviour. 
 h) “Negative” symptoms. 
 
 
Above-mentioned diagnostic criteria may leave a mistaken impression that 
people with chronic psychotic disorder have a uniform illness. In fact, they vary 
greatly with respect to their symptoms, course of illness, treatment response, 
and other characteristics – no two cases are ever exactly the same.  
The current thesis focuses on the stage of psychotic disorder that is com-
monly referred to as first-episode psychosis (FEP). Although there is no con-
sensus regarding the operational definition of FEP, it is typically used to 
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characterize individuals early in the course of a chronic psychotic disorder or its 
treatment. Recommended operational definition for FEP should contain at least 
three categories: (i) verifying first (antipsychotic) treatment contact; (ii) identi-
fying duration of antipsychotic medication use; and (iii) offering information 
about duration of above-mentioned psychotic symptoms (Breitborde et al. 
2009). Although this strategy will not control for the true underlying hetero-
geneity of the disorder, and firstly ascribed diagnoses, it provides a valuable 
method for homogenizing variability of patients used in such research projects.  
 
 
2.2. Clinical characteristics 
Schizophrenia is heterogeneous in its clinical presentation. However, there are 
believed to be at least five distinct symptom domains (Stahl 2013).   
Positive symptoms are psychotic behaviours not generally seen in healthy 
people. People with positive symptoms may “lose touch” with some aspects of 
reality. Positive symptoms include the following: hallucinations (sensory expe-
riences that occur in the absence of a stimulus), delusions (strongly held false 
beliefs that are not consistent with the person’s culture), thought dis-
orders (unusual or dysfunctional ways of thinking), movement disorders (may 
appear as catatonia as well as agitated body movements).  
 
Negative symptoms are associated with disruptions in emotions and behaviours. 
These symptoms include the following: “flat affect” (reduced expression of 
emotions via facial expression or voice tone), reduced feelings of pleasure in 
everyday life, difficulty beginning and sustaining activities, reduced speaking, 
lack of interest in other people, and lack of spontaneity. 
Affective symptoms such as depressed mood, suicidal thoughts or behaviour, an-
xious, guilt, tension, irritability, and worry frequently accompany schizophrenia.  
 
Aggressive and hostile symptoms include overt hostility, such as verbal or 
physical abusiveness; self-injurious behaviours; and different forms of property 
damage.  
 
Cognitive symptoms are widely recognized as a central core feature of the 
chronic psychotic disorder (Saykin et al. 1991; Gold & Harvey 1993; van Os & 
Kapur 2009). More than hundred years ago when the original name for 
schizophrenia was first used in its current form (model of Emil Kraepelin), it 
was called dementia praecox (premature dementia), a term that reflected the 
fundamental role of cognitive impairments associated with the disorder. 
Cognition can be defined as mental action or process (closely linked to the 
function of particular areas, neural pathways or cortical networks in the brain) 
that lead to acquiring information and knowledge, and drive how an individual 
understands, and acts in the world. Cognitive or neuropsychological functions 
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encompass such processes as perception, reasoning, memory and working 
memory, attention, problem solving, decision making, information processing 
speed, production of language and possess general knowledge, among others. 
The terms cognitive and neuropsychological will be implemented interchange-
ably in this thesis.  
Cognitive deficits are decline or impairment of cognitive function in one of 
the above-mentioned areas, which neuropsychological tests can be used to 
confirm. The concepts of deficit and impairment will also be used interchange-
ably in this thesis. Clinically significant cognitive impairment refers to the 
following condition: person's performance is one or more standard deviations 
below the control group mean in at least one or more cognitive domains, and the 
magnitude of the impairment is expected to have an impact on their everyday 
life.  
In schizophrenia, cognitive impairments are found across most domains: 
working memory (the ability to maintain and manage information for brief 
periods); verbal learning and memory (recalling verbal information for longer 
periods of time); attention/vigilance (the ability to stay focused on the task at 
hand without being distracted by other stimuli); processing speed (quickly 
responding to simple tasks); social cognition (recognizing facial expressions 
and understanding their meaning); reasoning and problem solving (effective 
strategy application); visual learning and memory (the ability to remember 
visual information for longer periods of time); episodic memory (mnemonic 
processes that record, retain, and retrieve autobiographical knowledge about 
experiences that occurred at a specific time and place); and executive functions 
(ability to plan, organize and complete tasks) (Gold & Harvey 1993; Heinrichs 
& Zakzanis 1998; Cirillo & Seidman 2003; Green et al. 2004; Reichenberg & 
Harvey 2007).   
Meta-analytic studies have shown that across cognitive domains the average 
impairment among patients with schizophrenia tends to be approximately one or 
more standard deviation below the healthy population mean (Dickinson et al. 
2007; Reichenberg & Harvey 2007; Mesholam-Gately et al. 2009).  
Although the cognitive deficit is considered to be universal in schizophrenia, 
there is considerable heterogeneity among patients (Joyce et al. 2005), and 
whether this heterogeneity reflects specific brain dysfunctions within distinct 
endophenotypes or individual variation in the effects of a general underlying 
pathophysiology is not entirely understood (Gur et al. 2006; Dickinson & 
Harvey 2009). Moreover, there are also schizophrenia patients with normal 
cognitive functioning (Palmer et al. 1997; Reichenberg et al. 2009). Estimates 
of the proportion of schizophrenia patients without neuropsychological impair-
ment varying from 16% (Reichenberg et al. 2009) to 27.5% (Palmer et al. 
1997). Being cognitively intact does not mean that patients necessarily have 
normal cognitive functioning as their impairment may be subclinical in absolute 
terms (Kremen et al. 2000). However, their profile of performance across 
multiple cognitive domains (i.e. relative strengths and weaknesses) is very 
similar to that of patients with obvious cognitive impairments (Holthausen et al. 
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2002), and their performance tends to be lower compared to their expected 
premorbid functioning (Reichenberg et al. 2002). Therefore, it is likely that 
almost all patients with schizophrenia are functioning below the level that 
would be expected in the absence of the illness (Keefe & Harvey 2012).  
Cognitive underperformance is consistently been shown to be present at 
onset of the illness (Bilder et al. 2000; Addington et al. 2003). Several studies 
have demonstrated that objectively measured impairments in cognitive 
functioning precede the onset of psychosis by almost decade (Seidman et al. 
2010), and cognitive deficits are found in the biological relatives of subjects 
with schizophrenia (Snitz et al. 2006), suggesting that aspects of cognition im-
paired in schizophrenia may be under genetic control. While positive and nega-
tive symptoms of schizophrenia can fluctuate, cognitive deficits remain relati-
vely stable from first-episode through to late middle age (Rund 1998; Heaton et 
al. 2001; Albus et al. 2006; Reichenberg et al. 2010; Aas et al. 2014), and it has 
been suggested that most of the decline occurs just before or within few years 
after the onset of psychosis (Bora & Murray 2014). Moreover, cognitive dys-
function tends to be fairly independent of psychotic symptoms (O’Leary et al. 
2000), minimally influenced by antipsychotic treatment (Kahn & Keefe 2013), 
related to underlying neuronal dysfunction (Kéri & Janka 2004), and predict 
patients’ everyday functioning in the community (Green 1996; Green et al. 
2004).  
Given the multitude of tests that show significant impairment, from basic 
sensory and perceptual functions through preconscious information processing 
and early attention to higher order cognition, there is clear evidence for a broad 
cognitive deficit in patients with schizophrenia (Dickinson et al. 2008).  
In nonclinical groups, the extensive factor analyses of John Carroll and 
others have firmly established that different cognitive measures correlate with 
each another positively. Data pertaining to scores of almost whichever cognitive 
test conform to a factor structure in which individual measures load on broader 
cognitive ability factors, which in turn load on a higher order factor (g) repre-
senting general cognitive ability (Carroll 1993; Deary et al. 2010). This is one 
of the most consistent observations in psychology, dating back to the work of 
Charles Spearman (1904). In schizophrenia, factor analysis supports sorting of 
cognitive test variables into cognitive domains that is at first sight largely 
consistent with the nonclinical literature (Allen et al. 1998; Dickinson et al. 
2002, 2011; Nuechterlein et al. 2004; Genderson et al. 2007), thereby sup-
porting the hypothesis that these constructs have similar meaning in the contexts 
of schizophrenia and healthy variability in cognitive abilities.  
However, schizophrenia studies have revealed that aforementioned cognitive 
domains (other than g) are highly overlapping and not necessarily valid inde-
pendent constructs (Gold et al. 1997). Moreover, even if the domains are dis-
tinguishable in one group of people, this does not guarantee the validity of their 
derived measures in different types of samples (e.g. inpatients/outpatients, first-
episode/chronic or the same sample at different time points). In other words, 
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covariance matrices of cognitive test scores may differ between different 
samples or within the same sample over time (Jaeger et al. 2003).  
The overwhelming evidence suggests that schizophrenia is essentially a dis-
order of subtle aberrations of brain development, plasticity, alterations of 
dopamine and glutamate as well as an interactive role between both neuro-
transmitters among others mechanisms and these disruptions manifest itself in 
cognitive impairment (Jindal & Keshavan 2008; Falkai et al. 2015; Howes et al. 
2015).  
While the investigations into impaired cognition in schizophrenia – its 
mechanisms, neural underpinnings, and methods for its treatment and rehabi-
litation – have become one of the most dynamic areas of schizophrenia re-
search, the field has begun to take advantage of the tools and constructs of 
experimental cognitive psychology (MacDonald & Carter 2002). Though no 
real consensus has been reached on cognitive test batteries for schizophrenic 
patients in non-pharmaceutical trials (Nielsen 2011).  
The use of computerized testing has increased during the later years pro-
viding methodological advantages compared to standard paper pencil tests. The 
main advantages are standardization of tests, greater accuracy and appropriate-
ness for cross-cultural comparison (Levaux et al. 2007).  
The CANTAB is a battery of computerized neuropsychological tests which 
have been developed by Cambridge Cognition company. CANTAB uses 
touchscreen technology and tests are designed in a game-like manner (Sahakian 
& Owen 1992). Neuropsychological tests from CANTAB provide opportunity 
to evaluate the individual’s test performance on the level of fundamental 
cognitive processes (Hutton et al. 1998; Leeson et al. 2009b) that are con-
ceptually linked to known neuroanatomical substrates (Owen et al. 1991; 
Pantelis et al. 1997; Rogers et al. 2000; Levaux et al. 2007; Leeson et al. 
2009b). Our investigation was based on eight CANTAB tests scores measuring 
a wide range of cognitive skills potentially sensitive to psychotic disorders. 
In order to establish the distinctive profile of cognitive functioning of pa-
tients experiencing FEP (i.e. how patients differ from healthy people), traditio-
nally the average performance of a patient sample in a set of tests is compared 
to that of control subjects with the same educational level and age. In contrast, 
patients’ change in cognitive performance is evaluated by comparing their 
cognitive test scores at baseline with follow-up scores. Patients' cognitive 
changes over time do not have to parallel how they differ from healthy people; 
in any given measure they can be stable, improve or decline, regardless of how 
they differed from healthy people at the baseline. 
An assumption underlying both between- or within-group comparisons is 
that the measurements are invariant – the tests have equivalent psychometric 
properties. In the other words, tests are measuring the same construct in the 
same way in different groups or over time/condition (Meredith 1993). However, 
in practice measurement invariance (MI) is rarely tested and therefore the 
conclusions may be incorrect. For example, an observed difference in test 
scores may result from a difference in only one specific type of items in the test: 
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in this case, the group difference does not in fact pertain to the general cognitive 
skill the test purports to measure but to the narrow one reflected in the specific 
group-sensitive type of items.  
Longitudinal studies may be characterized by several methodological issues, 
which need to be taken into consideration, such as growing familiarity with the 
test or testing environment, improvement of underlying functions, practice 
effects (McCaffrey et al. 2000), enhanced test taking strategies (Hausknecht et 
al. 2007) or individual characteristics (i.e. age, educational level) (Lezak 2012), 
as well as test-retest interval (Dikmen et al. 1999).  
Traditionally, cognitive dysfunctions as measured by objective tests have 
been considered as the gold standard of patients’ “true” cognitive functioning. 
However, besides the objectively measured profile of neuropsychological 
strengths and weaknesses of an individual, their subjectively perceived cogni-
tive dysfunction may reveal patients’ level of everyday functioning (Chaytor & 
Schmitter-Edgecombe 2003). Subjectively perceived cognitive impairment 
tends to be an important early indicator of schizophrenia as it precedes pro-
dromal symptoms (Nuechterlein & Dawson 1984; Hambrecht et al. 2002), and 
is prevalent among patients with FEP (Moritz et al. 2000) and during the 
chronic psychotic disorder (Stip et al. 2003; Homayoun et al. 2011). It is 
currently unclear to which extent subjective and objective cognitive dysfunction 
track each other (Zanello & Huguelet 2001; Prouteau 2004; Homayoun et al. 
2011). Findings suggest that subjectively perceived and objectively measured 
cognitive functioning might make unique contributions to advance our under-
standing of cognitive functioning in patients with schizophrenia (Stip et al. 
2003). Therefore, both should be implemented to give a broader perspective 
about patient’s cognitive functioning in deciding upon the appropriate clinical 
practice regarding the assessment and management of cognitive problems.  
 
 
2.3. The course of the disease 
The clinical and pathophysiological course of schizophrenia follows a fairly 
characteristic pattern depicted in Figure 1. (Lewis & Lieberman 2000).  
The typical course of schizophrenia includes a relatively normal childhood, 
interruptions in late adolescence or early adulthood accompanied by a dramatic 
deterioration from which few remit (Lewis & Lieberman 2000). Premorbid 
phase indicates the patient’s level of psychosocial functioning before any 
evidence of specific psychotic disorder; prodromal phase comprises the onset of 
mild fluctuating psychotic symptoms below the threshold for a psychosis 
diagnosis (it can last for weeks, months or even years, and symptoms in this 
phase include depressed mood, anxiety, irritability, disorganized thought, ideas 
of reference, magical thinking, illusions, deterioration in personal hygiene, 
social withdrawal, difficulties communicating with others, restricted drive, 
initiative or interest, and problems in cognitive functioning); the onset of 
symptoms is usually gradual and intermittent (Yung & McGorry 1996). 
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Psychiatric symptoms before the first-episode are not necessarily unique to 
schizophrenia. Progressive or psychotic phase marks the formal onset of 
schizophrenia and this is indicated by the FEP. Clinical deterioration is evident 
during this phase, and the psychotic phase progresses through an acute, a 
recovery or stabilization and a stable phase. The onset of symptoms in the acute 
phase is usually abrupt (mainly positive symptoms; i.e. delusions and hallucina-
tions) or insidious (mainly negative symptoms, such as social withdrawal). Re-
sidual phase describes the occasion when patients have residual enduring symp-
toms and functional disability. Outcome varies considerably across patients. 
 
 
Figure 1. Pathophysiological course of schizophrenia (adapted from Lewis & Lieber-
man 2000).  
 
 
There is a consensus that only one episode and remission are seen in 15–20% of 
patients. At the other side, about 15% will never effectively recover from their 
first episode, remaining symptomatic. Between these two poles, most patients 
will recover at least partly from their FEP, but will not return to their premorbid 
level of functioning or will suffer future relapses and a chronic course of the 
disorder with increasing residual symptoms (van Os et al. 2008). 
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2.4. Epidemiology  
The incidence of schizophrenia is about 0.20/1000/ per year (Messias et al. 2007). 
Due to the often chronic course of the illness, its prevalence is higher, being 
reported between 0.2 and 0.87% (Perälä et al. 2007; Wittchen et al. 2011). Men 
and women are approximately equally affected, but the peak incidence of onset 
tends to be later in females at around late-20s compared with early- to mid-20s for 
males (American Psychiatric Association 2013). Compared to other diseases of 
similar disabling effects but far higher prevalence, schizophrenia is one of 
costlier, if not the costliest burden to society, requiring a disproportionate share of 
mental health services and leading to significant work place drop out. In Estonia, 
schizophrenia ranked 15th and 8th in the list of causes of burden of disease, 
respectively for men and women (Reinap et al. 2005).  
 
 
2.5. Etiology 
2.5.1. Proposed causes of schizophrenia  
The pathogenesis of schizophrenia is presently hypothesized to comprise 
complex interactions between genetic and environmental factors (van Os et al. 
2008). In particular, the occurrence of such interactions is thought to underlie 
disease initiation during critical phases of human neurodevelopment (Rapoport 
et al. 2012).  
 
2.5.1.1.  Genetic risk factors  
The genetic basis of schizophrenia is widely acknowledged. The Schizophrenia 
Working Group of the Psychiatric Genomics Consortium (PGC-SCH) reported 
a minimum of 108 conservatively defined schizophrenia-associated genetic loci 
(Ripke et al. 2014). Several of these associations corroborate to the hypothesis 
that links dopamine (DA) with the etiology and treatment of schizophrenia. 
Also, the genetic associations support the roles of glutamatergic neurotrans-
mission and synaptic plasticity (Ripke et al. 2014). Furthermore, inflammatory 
and immune response genes have significantly altered expression in 
schizophrenia (Stefansson et al. 2009; de Jong et al. 2012) offering support for 
the general hypothesis that immune dysregulation plays a role in the disease 
manifestation (Tansey et al. 2015). 
 
 
2.5.1.2.  Environmental factors 
Genotype interacts with negative life events to contribute to individual diffe-
rences in the vulnerability and resilience to schizophrenia (Daskalakis & Binder 
2015). For mental disorders, the most influential environmental factors are 
adverse life events, such intra-uterine and perinatal complications (i.e. intra-
uterine growth retardation, viral infections, hypoxia, malnourishment), physical, 
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psychological and sexual abuse, negative emotionality in family environment, 
social adversity, complicated relationships, migration, urban residence, stress 
and drug abuse (especially cannabinoids, cocaine, amphetamine and phen-
cyclidine/ketamine), among others (Kelly & Murray 2000; van Os & Kapur 
2009). The role of these environmental exposures is moderated by their timing 
during the lifespan (Lupien et al. 2009; Daskalakis et al. 2013).  
 
 
2.5.1.3. Epigenetic mechanisms 
The common link between genes, environment and development of schizophrenia 
is attributable to the epigenetic modifications (i.e. active DNA methylation 
and/or demethylation of genes, especially within promoter regions; histone 
modifications, and noncoding RNAs) (Petronis 2004; Rutten & Mill 2009).  
 
 
2.6. Pathophysiology 
Despite considerable research into the origin and development of schizophrenia, 
the exact pathophysiological mechanisms of the disease have not yet been 
elucidated. The causes and mechanisms of the illness are complex; alterations in 
several brain regions and changes in the neurocircuits, neurochemical, meta-
bolic, oxidative balance and inflammatory system have been implicated.  
 
 
2.6.1. Alterations in neurotransmitter systems 
The neurobiology of schizophrenia is complex and involves the interplay of a 
number of neurotransmitter systems, including, among others, DA, serotonin, 
glutamate (Glu), gamma-aminobutyric acid (GABA), neuropeptides and cate-
cholamines (Carlsson 1988; Davis et al. 1991; Carlsson et al. 2001; Howes & 
Kapur 2009; Kantrowitz & Javitt 2010; Seeman & Seeman 2014). As neuro-
transmitter systems are dynamic, dysfunction in one system will lead to 
variations or compensatory mechanism in others (Figure 2).  
As depicted in Figure 2., main symptoms of schizophrenia can be theoreti-
cally explained by a hyperdopaminergic state existing in the mesolimbic path-
way and a hypodopaminergic state in the mesocortical pathways. The former 
results in positive symptoms and the latter leads to negative, and cognitive 
symptoms. Recent findings, however, indicate that disturbances in dopaminer-
gic transmission  are probably secondary to aberrant  N-methyl-D-aspartate 
(NMDA) receptor/glutamate system function (Carlsson et al. 2001; Kantrowitz 
& Javitt 2010; Howes et al. 2015).  
Furthermore it has been suggested, that dopaminergic model may be most 
appropriate for patients with primarily positive symptoms and rapid response to 
antipsychotic treatment, while NMDA glutamate receptor model may be more 
appropriate for individuals with more balanced positive/negative and cognitive 
symptoms and poor antipsychotic response (Kantrowitz & Javitt 2010). 
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2.6.2. Inflammatory, metabolic and oxidative stress  
processes in schizophrenia 
Several findings point to a link between neuroinflammation and or altered peri-
pherial inflammatory processes and the pathophysiology of schizophrenia 
(Potvin et al. 2008; Meyer et al. 2011; Miller et al. 2011; Beumer et al. 2012; 
Müller et al. 2015). Moreover, studies have highlighted that perturbations in 
immune system function seen in chronic psychotic disorders are related to im-
paired metabolism status of the patients (Mondelli & Howes 2014). In the case 
of psychiatric disorders, it is still not clear whether such peripherial effects on 
metabolism or on immune function are a cause or consequence of central 
nervous system disturbances. In addition, a growing body of evidence indicates 
that schizophrenia is associated with elevated oxidative stress status and im-
paired antioxidant defence (Flatow et al. 2013) and FEP is accompanied by 
oxidative stress (Sarandol et al. 2015).  
 
 
2.6.3. Neuropathological abnormalities 
Much of our current knowledge on the neuroanatomical basis of chronic 
psychotic disorder derives from structural imaging studies. It is now well 
established that schizophrenia is associated with structural brain abnormalities 
(Wright et al. 2000). Cerebral ventricular enlargement is one of the best 
replicated neuropathological finding (Selemon & Goldman-Rakic 1999), which 
is likely related to changes in other brain structures, including thinning of the 
surrounding cortex. Among FEP patients, multiregional and heterogeneous 
structural brain changes have been suggested, including grey matter (GM) 
volume reductions in frontal and temporal regions, the anterior cingulate cortex, 
the insula, the hippocampus, the parahippocampal gyrus and, possibly across 
the whole brain (Vita et al. 2006). However, these results have not always been 
replicated  (DeLisi et al. 1991; Molina et al. 2004). It has been suggested that 
cortical thinning (Rimol et al. 2012) or the surface area reduction (Sanabria-
Diaz et al. 2010) is the most important factor in volume reduction, with some 
suggesting that cortical folding differences could account for the some of the 
regional differences (Palaniyappan et al. 2011). Precise delineation of the 
neuropathology underlying schizophrenia in general, or its relations to neuro-
cognitive deficits, have remained elusive. Brain structural changes in psychotic 
disorder involve not just GM but also white matter (WM), which shows volume 
reduction across the whole brain (Wright et al. 2000), and alterations in a wide 
range of WM tracts within prefrontal and temporal lobes, as well as abnor-
malities within the fibre bundles connecting these regions (i.e. uncinate fasci-
culus, cingulum bundle and arcuate fasciculus) (Kubicki et al. 2007).    
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2.6.4. Decreased synaptic connectivity and  
dysconnection hypothesis 
There are several lines of evidence that developmentally reduced synaptic con-
nectivity in the neocortex and the hippocampus as well as quantitative and 
qualitative deficits in neuronal processes can account for important aspects of 
the schizophrenia (Panksepp 2004). In addition to neurodevelopmental dis-
turbances (Weinberger 1987), a concept of failure in regenerative capacities in 
disorder has been proposed (Falkai et al. 2015), involving disturbed neuro-
genesis (Toro & Deakin 2007), impaired synaptic plasticity (Schmitt et al. 
2011), and dysfunction of the dynamic interplay between neurons and oligo-
dendrocytes, which can lead to deficits in axonal function (Morrison et al. 
2013). A large number of neurophysiological and neuroimaging studies of 
patients with schizophrenia have provided evidence for dysconnectivity (i.e. 
abnormal functional integration of brain processes), which could manifest 
anatomically, through structural changes of association fibres at the cellular 
level, and/or functionally, through aberrant control of synaptic plasticity at the 
synaptic level (Stephan et al. 2009). The dysconnection hypothesis incorporates 
neurobiological findings (i.e. psychosis could result from abnormal modulation 
of NMDA-dependent plasticity by other neurotransmitter systems) with clinical 
and cognitive functioning findings (i.e. cognitive deficit) in individuals with 
schizophrenia (Friston 1998; Stephan et al. 2009).   
 
  
2.7. Treatment 
Currently there is no cure for schizophrenia. The primary goal of pharmaco-
logical treatment is to control psychotic symptoms. However, the ultimate goal 
is to optimize clinical outcomes by improving the patients’ subjective well-
being and quality of life (Lambert et al. 2006). It is clear that existing anti-
psychotics (antidopaminergic drugs) are able to reduce positive symptoms of 
schizophrenia in a significant number of patients, but the failure is most obvious 
in the case of negative symptoms and cognitive deficits, which remain key pre-
dictors of functional disability (Goldberg et al. 1993; Goldberg & Weinberger 
1996). Major initiatives are under way to find new nonpharmacological ap-
proaches for cognitive enhancement in schizophrenia. Cognitive remediation 
interventions are promising rehabilitation methods with the aim of improving 
cognitve performance, symptoms, and also patients' psychosocial outcomes 
(McGurk et al. 2007b). At present, the optimal management of a patient with 
schizophrenia requires the integration of a range of disciplines and approaches 
including antipsychotic medication, education and counselling of the patient 
and their family, and community-based rehabilitation as well as psychological 
and social support programmes, as indicated by case-management models of 
treatment (van Os & Kapur 2009). 
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3. STUDY RATIONALE 
The research presented in the current dissertation started in 2008. To the best of 
our knowledge, there have been no previous comprehensive studies of FEP in 
Estonia. To fill this gap we designed a longitudinal study of FEP patients to 
assess their cognitive functioning, brain anatomical structure, metabolic, inflam-
matory and oxidative stress biomarkers, genetic factors, as well as subjective 
well-being. To demonstrate disease specific factors, control subjects from the 
same geographical area were also recruited.  
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4. AIMS OF THE STUDIES 
The primary objective of the present thesis was to characterize the patients 
cognitive functioning at the early stage of the psychotic disorder and, in parti-
cular, to describe patients’ cognitive dysfunction and investigate its relation-
ships with brain morphology. The thesis also set out to examine the effects of 
demographic and clinical characteristics on cognitive function at the early stage 
of the psychotic disorder.  
The specific aims were the following: 
1) To characterize the structure of the cognitive functioning as well as cognitive 
performance profile and impairment magnitude of FEP patients compared to 
control subjects (CSs), measured by computer based cognitive tests from 
CANTAB (Paper I).  
 
2) To evaluate the rank-order and mean-level stabilities of FEP patients’ cog-
nitive abilities over a six month period immediately following diagnosis. To 
examine longitudinal measurement (CANTAB) equivalence and determine 
factors potentially linked to cognitive performance change in patients with 
FEP such as age, gender, educational level, treatment and psychopathology 
change scores. In addition, to compare patients subjectively perceived cog-
nitive functioning level with objective results of neuropsychological assess-
ment (Paper II).  
 
3) To identify the brain regions where morphological parameters, particularly 
cortical thickness (CTh) and cortical area (CA) relate to cognitive func-
tioning, by performing magnetic resonance imaging (MRI) and measuring 
neurocognitive performance using the CANTAB, in order to investigate any 
significant differences in brain structure/function associations between FEP 
patients and CSs (Paper III).  
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5. SUBJECTS AND METHODS 
The research project was approved by the Ethic Review Committee on Human 
Research, University of Tartu, Estonia. All procedures contributing to this work 
complied with the ethical standards of the relevant national and institutional 
committees on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2008.  
In terms of ethical, legal and human rights issues, individuals with psychotic 
disorder have long been considered a vulnerable group in the scientific research 
(Welie & Berghmans 2006). This group of persons may be restricted in their 
freedom to decide whether or not to participate in research. The answer to this 
question is essentially determined by the persons’ mental capacity to make an 
informed decision (Carpenter et al. 2000). However, having mental capacity is 
not equivalent to not having a specific psychiatric diagnosis, and vice versa 
(Berghmans 2001). Given the inherent potential for investigator bias, patients’ 
phychiatrists independently ascertained subjects’ mental capacities and provided 
information about the study. Afterward, there was possibility to discuss the study 
with principal investigator and other members of the research team. The research 
did not intervene in the treatment options and had minimal burdens and risks to 
the patients. More likely, participating was associated with potential benefits for 
the subjects, as they got more attention from healthcare workers.  
Prior to taking part, all participants were informed of the aims of the study, 
and of their freedom to participate or not, and their right to leave the study at any 
time. Patients were informed that their final decision would not influence the 
medical care they received. All participants provided written informed consent. 
 
 
5.1. Subjects 
The patient sample was recruited within an on-going longitudinal research 
project of first-episode psychosis of the Psychiatry Clinic of Tartu University 
Hospital, Estonia (Paper I, II, and III) and partially from the North Estonia 
Medical Centre, Tallinn Psychiatric Hospital (Paper I). The patients fulfilled the 
following inclusion criteria: aged between 18 and 45; experience of the first 
psychotic episode; duration of untreated psychosis less than 3 years; no anti-
psychotic treatment received before the first contact with medical services for 
psychosis. When recruited, patients were in the stabilization phase of the FEP 
(F23 or F20._9). Diagnoses were based on clinical interview according to ICD-
10 (WHO, 1992) criteria, medical chart review, interviews with collateral infor-
mants, and were consented within two clinical psychiatrists. Patients were 
taking their regular medications, including antipsychotics, during the study 
period. Patients were excluded from the study if they had psychotic disorders 
due to a general medical condition or substance induced psychosis.  
A sample of CSs was recruited by advertisement from hospital staff and the 
general public of the same geographical area. The CSs were questioned 
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regarding their current health status and medical history in order to exclude 
those with conditions that might interfere with cognitive performance. Con-
ditions that resulted in rejection of participants included neurological disorders, 
mental retardation or significant learning disorder, and major sight and hearing 
impairment. Exclusion criteria for the control group also included psychotic 
disorder among close relatives. Both FEP patients and CSs were required to be 
proficient in Estonian language.  
 
 
5.2. Methods 
5.2.1. Neuropsychological assessments  
Objective neuropsychological status was assessed using the comprehensive 
Cambridge Neuropsychological Test Automated Battery (CANTAB) (Robbins 
& Sahakian 1994). The ten tests included in the CANTAB have shown to be 
sensitive predominantly to the functioning of the frontal, temporal, frontotem-
poral, frontostriatal, frontoparietal and cingulate brain regions were admi-
nistered to the participants. These tests were considered likely to reflect a wide 
spectrum of cognitive dysfunctions among FEP patients. Computerized tasks 
from the CANTABeclipse version 3.0.0 were run on a personal computer with a 
high resolution touchscreen. All task stimuli were visual in nature, consisting of 
geometric designs or simple shapes, and required non-verbal responses. Instruc-
tions were given in Estonian from a literal translation of the CANTAB test ma-
nual produced by three clinical psychologists fluent in both English and Esto-
nian. The employed neuropsychological tasks are briefly described in the Table 
2 (and were characterized in the Supplementary materials of Paper I, not added 
extra to the dissertation). More detailed descriptions of these tests are available 
on the CANTAB® website (www.cambridgecognition.com).  
 
 
Table 2. Used CANTAB test battery description. 
MOT Motor Screening test  
 The test familiarise participants with the touchscreen tablet com-
puter. The procedure consists of a series of crosses shown in diffe-
rent locations on the screen, and the participant is asked to touch 
each cross using the forefinger of the dominant hand. 
This test was not used in the further analyses. 
Visual memory tests  
PRM Pattern Recognition Memory 
 The test relies on cued memory functions. It is presented in two 
phases. In the presentation phase, 12 abstract visual patterns are 
presented sequentially, in the centre of the screen. In the recognition 
phase, the subjects are required to choose between a familiar 
stimulus and a novel pattern.  
The total number of correct responses was used as the outcome. 
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SRM Spatial Recognition Memory 
 Subjects were required to learn the location of five identical squares, 
which were appearing one at time in different locations on the 
screen. In the recognition phase, two squares appeared simulta-
neously on the screen and the subject had to target the one in a 
familiar location.  
The total number of correct responses was used as the outcome. 
PAL Paired Associates Learning 
 The test assesses visual memory and learning. The task requires 
subjects to learn and then replicate the matching of two complex 
pattern-location associations. The number of pattern-location pairs 
then increases to three, six and finally to eight. At each stage, boxes 
are displayed on the screen and are opened in a randomized order. 
Two or more of them contain a pattern. The patterns shown in the 
boxes are then displayed in the centre of the screen, one by one, and 
the subject should touch the box where the pattern was initially 
placed. If the subject makes an error, the patterns are presented again 
to remind the subject of their locations.  
The first trial memory score (the number of patterns correctly 
located after the first trial summed across the stages completed) was 
used as the outcome. 
Executive function, planning, and working memory tests 
BLC Big/Little Circle  
 This test assesses comprehension, learning and reversal learning (the 
process of learning to inhibit previously rewarded actions), and is 
also intended to accustom participants on the general idea of 
following and reversing rule. This is screening test for IED.  
 This test taps visual discrimination and selective attentional set 
formation, and evaluates the maintenance, shifting, and flexibility of 
attention. Two dimensions are used in the test: colour-filled shapes 
and white lines. Subjects are required to alter behaviour according to 
changes in dimensional relevance of stimuli. At first, maintain 
attention to examples within a rewarded stimulus dimension 
(intradimensional shift), and then to shift attention to a different 
category that was previously irrelevant and unrewarded stimulus 
dimension (extradimensional shift). This test is primarily sensitive to 
changes to the fronto-striatal areas of the brain.  
The total number of reverse errors at the level of extradimensional 
shift was used as the outcome. 
SOC Stockings of Cambridge  
 This is a spatial planning test, which gives a measure of frontal lobe 
function. The subjects must operate with the coloured balls in the 
lower display to reproduce the pattern shown in the upper display by 
moving balls with minimum number of runs. The time taken for 
completing the task and the number of moves required are taken as 
measures of the subject’s planning ability. 
The total score of problems solved in minimum moves was used as 
the outcome measure in this research.   
The test was not used in the further analyses. 
IED Intra/Extradimensional Shift 
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The participants completed the tests in a fixed order: MOT, PRM, SRM, PAL, 
BLC, IED, SOC, SSP, SWM, RVP. 
 
 
  
SSP Spatial Span 
 
This test gives a measure of the subject's visuo-spatial short term 
memory span. A set of squares is shown on the screen. Some of the 
squares change in colour, one at time. The subject has to touch each 
of the boxes highlighted by the computer and do it in the same order. 
The task starts with a small number of blocks presented at a time 
and gradually increases up to nine blocks. The test measures both 
the number of correct sequences and the longest sequence 
remembered. The dorsolateral prefrontal cortex (DLPFC) plays a 
key role in short memory span.  
The longest sequence successfully recalled by the subject was used 
as the outcome. 
SWM Spatial Working Memory 
This test evaluates the subject’s ability to retain spatial information 
and to manipulate memorized items in the working memory. A trial 
begins with a number of coloured squares (boxes) being shown on 
the screen. The overall aim is that the subject should find a blue 
‘counter’ in each of the boxes, by using a process of elimination, 
and use them to fill up an empty column on the right hand side of 
the screen. The subject must touch each box in turn until one opens 
with a blue ‘counter’ inside. Participants must avoid touching boxes 
that they have been found to be empty, and revisiting any box in 
which a blue ‘counter’ has already been found. Choosing these 
options are encoded as errors. The subjects choose the order in 
which the boxes are searched, and an estimate of the use of the 
heuristic strategy is measured by counting the number of times the 
subject begins a new search with a different box. A high score 
represents poor use of the suggested heuristic strategies.  
The total number of errors and ineffective strategy score were used 
as the outcomes. 
RVP Rapid Visual Information Processing 
 
This test is a sustained vigilance task, and the subject must identify 
consecutive odd or sequences of digits, which appear in a pseudo-
random order, at the rate of 100 digits per minute.  Participants are 
instructed to detect target sequences of digits (3-5-7, 2-4-6, and 4-6-
8) and to register responses using the press pad. The test outcome 
measures are based on the signal detection theory and cover latency, 
sensitivity and specificity for detecting goal sequences.  
The probability of a correct hit (sensitivity for detecting sequences) 
was used as the outcome. 
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5.2.2. Magnetic resonance imaging acquisition and processing 
Multi-modal MRI scans were obtained using a Philips Achieva 3 Tesla MRI 
scanner at Tartu University Hospital, Estonia.  
Cortical surface reconstruction, volumetric segmentation and inter-group 
comparative correction were performed using the software FreeSurfer v5.1.0 
(http://surfer.nmr.mgh.harvard.edu), according to standardized procedures (Sled 
et al. 1998; Dale et al. 1999; Fischl & Dale 2000; Fischl et al. 2002, 2004; 
Ségonne et al. 2007). The surfaces were averaged across participants using a 
non-rigid high-dimensional spherical averaging method that aligned cortical 
folding patterns and matched morphologically homologous cortical locations 
across subjects on the basis of each individual’s anatomy while minimizing 
metric distortion (Fischl et al. 1999).  
The CTh was calculated as the average of the distance from the WM surface 
to the closest point on the pial surface and back (Fischl & Dale 2000).  
The CA estimation was generated according to WM surface geometry and 
characteristics obtained by computing the area of a triangle in a standardized, 
spherical atlas space surface tessellation when mapped in an individual 
subject’s space. We utilised the mapped differences between FEP and CSs in 
CTh and CA across the whole brain.  
Computations were carried out in the High Performance Computing Centre 
of the University of Tartu, Estonia. 
 
 
5.2.3. Clinical assessments   
Clinical symptoms were rated using the Brief Psychiatric Rating Scale (BPRS) 
(Overall & Gorham 1962), which is a widely used instrument for assessing the 
positive, negative, and affective symptoms of individuals who have psychotic 
disorders. The BPRS consists of 18 symptom constructs and each item is mea-
sured along a seven-point continuum from ‘not present’ to ‘extremely severe’. A 
total score, as well as positive and negative BPRS symptom scores (derived from 
the subscales identified by Ventura et al. 2000), were used as the outcomes. 
 
 
5.2.4. Subjective cognitive functioning 
Patients’ subjectively perceived cognitive functioning was evaluated by ’Mental 
functioning’ subscale, obtained from Subjective Well-Being under Neuro-
leptics-Short Form (SWN-K, Naber et al. 2001) Estonian version (SWN-K-E, 
Haring et al. 2013). The SWN-K consists of 20 items that are rated on the 6 
point Likert type self rating scale referring to the subjective experiences in the 
past 7 days. One of the subdimension, specifically the Mental functioning sub-
scale was used, which comprised following four items: “I find it easy to think”, 
“I am imaginative and full of ideas”, “My thinking is difficult and slow” and 
“My thoughts are flighty and undirected. I find it difficult to think clearly”. 
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Values of last two items were reversed during the scoring and higher global 
score indicated better mental functioning.    
 
 
 5.3. Statistical analysis 
5.3.1. Demographic and clinical variables  
Associations with demographic variables were analysed using t- and chi-square 
tests.   
 
5.3.2. Cognitive variables  
Differences in neuropsychological performance between FEP patients and CSs 
(Paper I, III) were evaluated using general linear models (GLMs) and were 
adjusted for age, gender, and educational level. In both groups, cognitive test 
scores were transformed into standard scores based on the means and standard 
deviations of the respective tests in CSs.  
GLMs were also performed to quantify individual-level changes in cognitive 
ability test scores over time (Paper II), wherein follow-up scores were predicted 
from baseline scores, controlling for age, gender and educational level. Devia-
tions from individuals' predicted scores (regression residuals) at the follow up 
were taken as their individual change scores (ICSs).  
Effect sizes were interpreted as small, moderate, and large, with cor-
responding Cohen’s d ranging from 0.2–0.49, 0.5–0.79, and ≥ 0.8, respectively 
(Cohen 1977). 
To compare the co-variance structure of the measured neuropsychological 
tests across the groups (Paper I), and to investigate the structure of the patients 
ICSs (Paper II), a principal component analyses (PCA) were performed as the 
first steps.  
Second, for each PCA a parallel analysis (Horn 1965) helped determine the 
most appropriate number of components to be retained.  
As the components were expected to be correlated each PCA was followed 
by an oblique (oblimin) rotation.  
In order to determine whether PCA results were plausible reflections of latent 
cognitive constructs confirmatory factor analyses (CFAs) were conducted.  
Third, to assess whether: a) the structure of latent cognitive traits was similar 
in patients and controls; b) the mean scores of each group could be meaning-
fully compared (i.e. measurements were invariant across the groups, MI) (Paper 
I), and c) the cognitive traits structure replicated across the two testing occa-
sions (Paper II) multi group confirmatory factor analyses (MGCFA) (Joreskog 
1971; Widaman & Reise 1997; Widaman et al. 2010) were used. As is common 
in MI testing (Wicherts & Dolan 2010) a series of multi-group CFA models 
were fitted with systematically increasing parameter equality constraints across 
groups (Paper I) or within the group, across testing occasions (Paper II) (Horn 
& McArdle 1992; Vandenberg & Lance 2000).  
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For MI testing, configural invariance was met if the same variables were 
associated with the same latent factors between groups or within the FEP group 
over time. No parameter equality constraints were imposed at this point other 
that the same tests defined the same latent constructs. The configural invariance 
model served as a baseline for further comparisons.  
Weak invariance was achieved when the factor loadings of the CANTAB tests 
on the latent variables could be held constant across the groups or within the FEP 
patients group over time without a significant deterioration of model fit. Weak 
invariance provides evidence that latent factors have the same meaning across 
FEP patients and CSs as well as for FEP patients group over time.  
To establish a stronger form of invariance, strong invariance, both factor 
loadings and intercepts of tests were constrained to be the equal across con-
ditions. In the case of no significant deterioration in model fit, scores of latent 
factors could be considered comparable across the groups and for the FEP 
patients group over time.  
Strict invariance (residual variance invariance) was also explored. No 
deterioration of model fit with strict invariance indicated that neuropsycho-
logical variables were measured with the same precision in both occasion.  
Finally, variances and covariances of the latent traits were constrained to be 
equal between groups and within the patients group across testing occasions to 
test whether the variability and inter-correlations of the latent variables were 
similar. Models were fitted using the robust maximum-likelihood (MLR) esti-
mator in the 'lavaan' package (Rosseel 2012). Models fit was estimated using the 
chi-square (χ²) goodness-of-fit statistic (Hu & Bentler 1999), the Comparative Fit 
Index (CFI) (Bentler 1990) and the Root Mean Square Error of Approximation 
(RMSEA) (Browne & Cudeck 1993; Hu & Bentler 1999; Steiger 2000).  
Any given type of MI was supported when the fit of the more parsimonious 
model (e.g. the model with intercept equality constraints) was not significantly 
poorer than that of the less constrained model (e.g. the one without intercept 
equality constraints). Differences in models fit were tested using the chi-square 
difference test (Horn & McArdle 1992), where a statistically significant (p < 
0.05) Δχ2 indicated a difference in fit. Differences in latent factors were 
estimated by fixing the mean scores in one group or mean scores at first testing 
at zero and freely estimating the means of the other group or follow-up testing.  
Next, in order to examine rank-order stability across the two testing occa-
sions, Pearson’s correlation analysis was used (Paper II).  
In order to evaluate whether significant change in the cognitive characte-
ristics had occurred because of FEP patients age, gender, educational level, 
clinical symptom severity or treatment-related variability, psychopathology 
change score (BPRS CS), antipsychotics equivalent dose change (AP DC) were 
calculated and cognitive ICSs were separately regressed on BPRS CS’s, AP 
DC’s and demographic variables, using random coefficients models (RCMs) 
(Paper II). Furthermore, correlations between performance in cognitive test 
scores and subjectively perceived mental functioning were analysed at baseline 
and after the six month follow-up using a Pearson correlation test (Paper II). 
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Analyses were conducted using the R Statistical software package (R: Core 
Team 2013, 2015). 
 
 
5.3.3. Imaging variables 
For the analysis of whole brain neuroanatomical alterations (Paper III), the 
vertex-by-vertex analysis was used and CTh and CA values from the significant 
clusters of all subjects were modeled as a function of group (FEPs vs. CSs). The 
simulation and clustering approach is implemented in FreeSurfer and signi-
ficance level (p < 0.05) is obtained through a combination of a probability thres-
hold and cluster size threshold. The p-values of the resulting clusters of the 
original data are expressed as cluster-wise probability (Pcw), and hereby Pcw is 
equivalent to the overall significance level (p < 0.05). The statistical maps of 
voxels sensitive to cognitive tasks were created using GLMs. The voxel-based 
GLMs were utilised to determine the unique contribution of MRI measures on 
cognitive test raw scores that were significantly different between groups. Tool 
from the FreeSurfer - QDEC (Query, Design, Estimate, Contrast) was used. Age 
and gender were used as covariates in all models. Left and right hemispheres 
were analyzed separately. To correct for multiple comparisons, statistical maps 
were thresholded to yield an expected false discovery rate (FDR) of 5% 
(Genovese et al. 2002) and that threshold was subsequently applied to the all 
CTh and CA maps.  
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6. RESULTS 
6.1. Paper I 
6.1.1. Demographic features of the subjects  
One hundred and nine (54.1% males, mean age 26.9 years) clinically stabilized 
patients with FEP participated in the study. CSs consisted of 96 subjects (40.6% 
males, mean age 25.7 years). No significant differences in age or gender were 
found. The patients average formal educational experience was significantly 
lower (t = -3.51, p < 0.01) compared to CSs.   
 
 
6.1.2. Principal component analysis and  
confirmatory factor analysis 
PCAs and CFAs were carried out separately in CSs and FEP patients groups.  
Whereas the scree plot and parallel analysis suggested extracting two com-
ponents for CSs and one component for FEP group, both solutions were tested 
in both groups. 
In the CSs group, the results indicated that five CANTAB subtest scores 
(PRM, PAL, SRM, RVP and SSP) primarily defined a component representing 
“attention/memory” (factor loadings 0.46–0.73) and four variables (SWM 
errors, SWM strategy, SOC and IED) primarily defined a component of “execu-
tive function” (factor loadings 0.40–0.84). The two-factor loading pattern with 
regard to FEP patients group demonstrated that: two variables (PRM and PAL) 
primarily defined the “memory component”, whereas seven variables (SRM, 
RVP, SSP, SWM errors, SWM strategy, SOC and IED) defined the “attention/ 
executive function component” (with primary loadings ranging from 0.42 to 
0.76). Importantly, we demonstrated that component intercorrelations also 
differed across groups, with 0.15 for controls and 0.30 for patients. Intercorre-
lations suggested a higher-order factor, a putative single common cause for all 
tests performance may underly the memory/attention- and executive function-
related sources of variance especially strongly among patients.  
Examination of the one-component PCAs solutions indicated that the 
CANTAB tests could also be grouped into a single high-order factor such that 
all variables loaded on a broad cognitive variable, with loadings of 0.19–0.66 in 
the control group and 0.30–0.85 in the patient group.  
Above-mentioned one- and two-component models derived from the PCAs 
results were subsequently converted to latent trait models for single-group 
CFAs (i.e. separate models were specified for FEP and CSs groups).  
In the two-factor model latent factors (“attention/memory” and “executive 
function”) were defined by the same variables for both the patient and control 
groups (see Figure 3 a) and b) for factor loadings and covariance estimates). All 
factor loadings (excepted IED) were significant at p < 0.01. Although interrelations 
among cognitive factors are typical, our results revealed a very strong inter-
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correlation between “attention/memory” and “executive function” among patients 
(r = 0.83) that supported the low distinctiveness of the two cognitive domains and 
provided strong evidence for a higher-order trait among them. In the CSs group the 
intercorrelation of “attention/memory” and “executive function” was much lower (r 
= 0.31). In other words, the two cognitive domains were more coherent among 
patients – when patients’ cognitive functioning was poor, it tended to be poor across 
most skills measured in the study, more so than among CSs.  
In the one-factor model (see Figure 3 c) and d)) all loadings were significantly 
different from zero in the patient group (z-values ranged from 2.14 to 9.00), 
whereas SWM errors, SWM strategy and IED had non-significant factor loadings 
(p = 0.09, p = 0.23 and p = 0.66, respectively) in the control group, indicating that 
this model may be less appropriate than the two-factor model for the latter group. 
 
Figure 3. Representation of the two- (a, b) and one- (c, d) latent factor structural models 
derived from principal component analysis for the control (a, c) and FEP (b, d) samples, 
respectively. Variables in boxes represent observed measures and variables in ovals 
represent latent variables. The paths from the latent constructs to the observed variables 
demonstrate the parameter estimates onto its representative constructs. Two-headed 
arrows connecting latent variables represent correlations between the constructs. The ‘e’ 
represents the unique variance and error associated with observed variable.  
PRM, pattern recognition memory; SRM, spatial recognition memory; PAL, paired 
associates learning; RVP, rapid visual information processing; SSP, spatial span; SWM, 
spatial working memory; SOC, Stockings of Cambridge; IED, intra/extradimensional shift. 
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The CFA models provided support for the hypothesized two- and one-factor 
solution. Model fit was good in both cases (χ2(25) = 14.85; CFI = 1.00;  
RMSEA = 0.00 and χ2(25) = 13.54; CFI = 1.00; RMSEA = 0.00, respectively for 
FEP patients group). Also for CSs group, both two- and one-factor models 
demonstrated acceptable fit (χ2(25) = 29.07; CFI = 0.96; RMSEA = 0.04 and 
χ2(25) = 28.95; CFI = 0.96; RMSEA = 0.04, respectively).   
Whereas, both one- and two-factor models fitted well in both samples, the 
decision was made to take both models forward to MGCFA.  
 
 
6.1.3. Measurement invariance analysis  
Multi-group CFA can be used to simultaneously test whether a hypothesized 
factor structure fits equally well in different groups.  
For the two-factor solution, the fit of the configural MI model (i.e. configural 
invariance is met when indicator variables load on the same factors across 
groups) was good (χ2(50) = 42.61; CFI = 1.00; RMSEA = 0.00), indicating that 
the two-factor dimensional structure was shared across groups and justifying the 
evaluation of more restrictive invariance models.  
Weak MI (i.e. weak invariance is met with adequate model fit when factor 
loadings are held constant across groups) was marginally supported (Δχ2(9) = 
15.68,  p = 0.07 (p-value corresponds to Δχ2) ; CFI = 0.998; RMSEA = 0.01), 
suggesting that the CANTAB subtests measured the cognitive abilities more or 
less similarly across groups.  
Strong MI (i.e. strong invariance is met when both factor loadings and 
intercepts are held constant across groups) was clearly not supported in these 
data (Δχ2(7) = 200.73, p < 0.00; CFI = 0.54; RMSEA = 0.14), indicating that the 
same observed CANTAB test scores corresponded to different latent trait levels 
in the two groups, making comparisons of their mean latent scores effectively 
meaningless. As strong MI was not met, testing for stricter forms of MI was not 
justified. 
In MGCFA specifying just one latent factor, the configural MI model fitted 
data well (χ2(50) = 41.97; CFI = 1.00; RMSEA = 0.00).  
The weak MI model was accompanied by a clear drop in model fit (Δχ2(9) = 
21.89, p < 0.01; CFI = 0.98; RMSEA = 0.03), suggesting that stricter forms of 
MI would not be met and latent factor means would not be comparable across 
groups. 
 
6.1.4. Comparison of cognitive performance 
According to MI results, comparison of cognitive performance measured by 
CANTAB between CSs and FEP patients could not be compared based on 
latent traits and group differences therefore had to be tested using observed test 
scores. GLM analyses were performed to demonstrate group differences in each 
cognitive measure, including age, gender and years in education as covariates in 
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all comparisons. In general, patients exhibited widespread cognitive impair-
ments compared to CSs. The profile of neuropsychological impairment in FEP 
patients (Figure 4) was most prominently characterized by diminished pro-
cessing speed (RVP) and impaired executive functioning (SWM errors, SOC 
and IED).  
In more details, there were significant main effects for visual (PRM) and 
spatial recognition memory (SRM) (F(4,200) = -5.65, p < 0.001, Cohen’s d = -0.69,  
and F(4,200) = -7.73, p < 0.001, d = -0.78, respectively), indicating that FEP 
patients gave a lower number of correct responses than CSs. Patients also 
showed diminished ability to learn and remember pattern-location associations 
during the first trial (PAL) compared to CSs (F(4,200) = -11.98, p < 0.001, d =  
-0.73), demonstrated difficulties in detecting important sequences during the 
sustained attention task (RVP) (F(4,199) = -18.02, p < 0.001, d = -1.17) and had a 
shorter spatial span length in the working memory capacity task (SSP) (F(4,200) = 
-10.4, p < 0.001, d = -0.61). In the executive functioning task (SOC), patients 
ability to solve problems with minimum number of runs was to a great extent 
diminished (F(4,200) = -18.28, p < 0.001, d = -1.36), and in the attentional shifting 
and flexibility task (IED), they made significantly more total reverse errors 
(F(4,200) = 11.38, p < 0.001, d = 1.25) compared to CSs. 
 
 
 
                  
Figure 4. Cognitive impairment profile: performance of FEP patients expressed as 
effect sizes. The sign of the effect size values was changed for IED and SWM domains 
in order to have the dysfunctional poles as negative values. 
PRM, pattern recognition memory; SRM, spatial recognition memory; PAL, paired 
associates learning; RVP, rapid visual information processing; SSP, spatial span; SWM, 
spatial working memory; SOC, Stockings of Cambridge; IED, intra/extradimensional shift.  
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Furthermore, FEP patients gave less correct responses in the SWM task (SWM 
errors) that measured a subject’s ability to retain spatial information and 
manipulate remembered items in working memory (F(4,200) = 9.92, p < 0.001, d = 
0.94), and also used heuristic strategies (SWM strategy) less efficiently than did 
CSs (F(4,200) = 8.92, p < 0.001, d = 0.67). 
 
 
6.2. Paper II  
6.2.1. Demographic and clinical features of the subjects  
Eighty-five patients (mean age 26.99, s.d = 6.96, 54.12% males) with FEP were 
included in the study. At the time of recruitment, patients were in the stabili-
zation phase of the disease (mean general psychopathology score, measured by 
BPRS was 24.18 (s.d. = 12.80)). The mean medication exposure time at 
baseline neuropsychological testing was 21.42 (s.d. = 8.92) days and the mean 
daily dose of the antipsychotic treatment in chlorpromazine (CPZ) equivalent 
(Gardner et al. 2010) was 387.38 mg/day (s.d. = 165.44). Follow-up measure-
ments were conducted approximately six months later (mean duration between 
baseline and follow-up testing was 191 (s.d = 27) days), and data were available 
for a total of 82 patients (96.47%), two patients drop out from mental health 
care system, and one refused to participate in the follow-up. During the follow-
up mean psychopathology (BPRS) score was 19.31 (s.d. = 11.37), and mean 
CPZ dose equivalent was 319.97 mg/day (s.d. = 183.31). BPRS scores and CPZ 
equivalents differed significantly between two sessions (t = -4.24; p < 0.0001, 
and t = -3.02; p = 0.003, respectively).  
 
 
6.2.2. Mean-level change   
When patients' tests pattern of mean-level changes across occasions were 
examined, there appeared small improvements in set-shifting (IED, t = -2.64,  
p < .05), speed of processing (RVP, t = 2.96, p < .05) and executive functioning 
(SOC, t = 3.80, p < .001) as well as in strategy usage and ability to manipulate 
spatial information in working memory (SWM strategy score, t = -5.25,  
p < .001, SWM errors score t = -5.40, p < .001). The differences in effect size 
units were: -0.33, 0.29, 0.42, -0.45, -0.42, respectively.  
Additionally, at the group level patients demonstrated worsening perfor-
mance in episodic memory (PAL, t = -10.84, p < .001) and spatial recognition 
memory (SRM, t = -6.20, p < .001) tasks; the magnitudes of these changes were 
large (-1.31, and -0.94, respectively). Spatial working memory (SSP, t = 0.49,  
p > 0.05) and pattern recognition memory (PRM, t = 1.35, p > 0.05) tests 
showed mean-level stability over time.  
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6.2.3. Six months stability of cognitive functioning   
FEP patients rank order of measured tests scores showed very high stability 
over time. Following rank-order stability coefficients of the cognitive tests were 
found: PRM, r = 0.89; SRM, r = 0.94; PAL, r = 0.84; IED, r = 0.80; SOC,  
r = 0.82; SSP, r = 0.92; SWM strategy score, r = 0.90, SWM errors score, r = 
0.84, and RVP, r = 0.83. All correlation coefficients were significant at 
p < 0.001.  
Patients’ relative standings within the group across the six months interval 
being very stable suggested that mean-level changes tended to characterize most 
of them in similar ways. These estimates also represent the lower-boundary 
estimates of the reliability of the tests in psychotic patients (true reliability 
might be higher because the observed changes could reflect substantive changes 
in addition measurement error). 
 
 
6.2.4. Structure of cognitive function and measurement 
invariance between six month time interval among FEP patients 
To investigate the structure of the patients ICSs (i.e. deviations from indi-
viduals' predicted scores at the follow up), a PCA was performed as the first 
step.  
One-factor (broad ability factor) solution accounted for 19% of the total 
variance among the nine CANTAB subtest scores in the baseline assessment of 
the FEP patient group and primary loading values ranged between 0.13 and 
0.82.  
CFA confirmed that the empirical model in which measures of CANTAB 
subtests loaded on one “broad ability” domain demonstrated excellent fit for the 
data (χ2(27) = 25.45; CFI = 1.00; RMSEA = 0.00).  
In order to evaluate MI across two time-point factor analyses, MGCFA was 
used. One-factor model demonstrated excellent fit (χ2(54) = 69.28; CFI = 0.95; 
RMSEA = 0.058), suggesting it could be considered a feasible representation of 
the data across both time-points and justifying the evaluation of more restrictive 
invariance models.  
At the level of weak invariance testing, model fit remained acceptable  
(Δχ2(8) = 6.43, p = 0.60; CFI = 0.96; RMSEA = 0.051), indicating that estimated 
factor loadings were not significantly different between two time-points.  
Indices of both relative and absolute model fit did not support the existence 
of the strong invariance (Δχ2(8) = 121.32, p < 0.001; CFI = 0.59; RMSEA = 
0.147), showing that intercepts values varied significantly between two assess-
ments. As strong measurement invariance was not met, testing for stricter forms 
of invariance were not justified. 
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6.2.5. The relationship of cognitive change with other variables 
In order to evaluate individual-level effects of demographic characteristics (age, 
gender, educational level), BPRS CSs and AP DCs on ICSs of neuropsycho-
logical functioning over time, RCMs were used. For SRM, PAL, IED, SOC, 
SWM errors and strategy usage scores the models reached statistical signifi-
cance levels (t = -6.26, p < 0.001; t = -10.33, p < 0.001; t = -2.02, p < 0.05;  
t = 2.76, p < 0.01; t = -4.14, p < 0.001; t = -4.38, p < 0.001; t = 2.29, p < 0.05, 
respectively).  
Gender was a significant predictor of IED, SOC, SSP, and SWM test per-
formances. Specifically, Figure 5 shows that gender differences (a) at baseline 
levels of performance and (b) in longitudinal rates of change were significant 
for the IED, SOC, SSP, and SWM (i.e. SWM errors and strategy score) tests, 
with males outperforming females (β = 0.44, p < 0.01, β = -0.49, p < 0.01,  
β = -0.58, p < 0.01, β = 0.50, p < 0.01 and β = 0.58, p < 0.01, respectively).  
 
 
 
Figure 5. Predicted mean levels of cognitive performance separately for men and women 
at baseline (a) and follow-up (b). Results are based on random coefficient models.  
PRM, pattern recognition memory; SRM, spatial recognition memory; PAL, paired 
associates learning; IED, intra/extradimensional shift; SOC, Stockings of Cambridge; 
SSP, spatial span; SWM strategy, spatial working memory, strategy score; SWM errors, 
spatial working memory, errors score; RVP, rapid visual information processing.  
Lower values (less errors and less ineffective strategy usage) for IED and SWM 
measures and higher values for PRM, SRM, PAL, SSP, and RVP indicate better perfor-
mance.   
 
Therefore, cognitive decline tended to be somewhat more pronounced among 
the female patients. In addition, longer time in education was predictor for 
downward change in IED (β = -0.22, p < 0.05) and upward change in the RVP 
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(β = 0.30, p < 0.01) test performances. Younger age was associated with de-
creases in SRM (β = -0.26, p < 0.05), PAL (β = -0.26, p < 0.01), and SSP (β =  
-0.22, p < 0.05) and increases in the strategy score of SWM (β = 0.20, p < 0.05).  
BPRS CS was not found to be a significant predictor of changes in the scores of 
any cognitive test. We conducted additional RCM analyses to separately 
evaluate the BPRS negative and positive symptoms change scores effects (in 
addition to gender, age, education and AP DCs) on the cognitive tests ICSs. We 
did not detect any statistically significant effects of negative symptoms change 
score, measured by BPRS negative symptoms subscale, on the cognitive perfor-
mance ICSs (t-values ranged between -1.84 to 1.16). BPRS positive symptoms 
subscale change score was a significant predictor for SWM errors ICSs (t = 
2.17, p < 0.05) and information processing (RVP) ICSs (t = -2.21, p < 0.05). 
In addition, significant associations were found between the mean daily AP 
DCs and patients' changes in the performance of SOC (β = -0.16, p < 0.05), and 
SSP (β = -0.16, p < 0.05), indicating that significant improvement in the 
performance occurred when AP dose diminished.  
Individual antipsychotic dose and psychopathology raw scores were signi-
ficantly correlated at the baseline and during the follow-up assessment (r = 
0.35, p = 0.001; r = 0.34, p = 0.002, respectively).     
 
 
6.2.6. Correlation between objective and  
subjective cognitive functioning 
No significant associations were found between the objectively and subjectively 
measured cognitive functioning neither at baseline nor at follow-up in FEP 
group (correlation coefficients ranged from r = -0.22 to 0.17, p > 0.05).     
 
 
6.3. Paper III 
6.3.1. Demographic and clinical features of the subjects  
The FEP patient sample consisted of 63 participants (mean age 25.6, s.d = 5.5; 
52.38% males). Patients had received an average of 22 (s.d. = 9) days of treat-
ment prior to the neuropsychological testing. Neuropsychological assessments 
and image acquisition (an average of 2 (s.d. = 6) days apart) were performed 
when the patients were clinically stable (mean general psychopathology score, 
measured by BPRS was 23.42 (s.d. = 12.81)) and able to tolerate these 
procedures.  
A CSs sample included 30 participants. The mean age of this sample was 
25.1 years (s.d. = 6.1) and a gender composition of 50% males. Differences 
between the groups with respect to the age, gender and years of formal edu-
cation were not significant (t(91) = 0.37, p = 0.71;  χ2(1) = 0.05, p = 0.83; t(91) =  
-1.59, p = 0.12, respectively).  
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6.3.2. Group differences in cognitive performance 
Main effects of group were significant in all measured domains: set shifting task 
(IED) (F(4,88) = 3.40, p = 0.001, Cohen’s d = 1.22), executive functioning task 
(SOC) (F(4,88) = 5.35, p < 0.001, d = -1.72), working memory task (SSP) (F(4,88) = 
10.39, p < 0.001, d = -0.91), spatial working memory (SWM errors score) 
(F(4,88) = 5.71, p < 0.001, d = 1.54), spatial working memory (SWM strategy 
score) (F(4,88) = 4.31, p < 0.001, d = 0.61), and information processing (RVP) 
(F(4,88) = 9.64, p < 0.001, d = -1.55). Positive parameter estimates (effect sizes) 
for SWM and IED indices demonstrate higher scores but worse performance in 
FEP patients group, and negative parameter estimates for SOC, SSP, and RVP 
refer to lower scores and worse performance in FEP patients group.  
Cognitive functioning characteristics presented in effect size units here are 
somewhat different compared to the values demonstrated before (Paper I, 
Figure 3): this is because we used only partly overlapping subsamples (i.e. here, 
the sample comprised FEP patients and CSs who had both cognitive functioning 
and MRI data). Nevertheless, the same trend emerged: FEP patients performed 
significantly worse than CSs on all measured neuropsychological tests, indi-
cating broad impaired cognitive functioning. 
 
 
6.3.3. Disease related cortical thickness and area differences 
6.3.3.1. Group comparisons of CTh and CA  
Brainmaps of the significance of group differences in CTh and CA were visua-
lized by colour bar (Figure 6). Red/yellow colours encode the significance of 
thicker cortex (a) and larger surface area (b), blue colours encode the signi-
ficance of thinner cortex (a), and grey for zero difference in FEP patients as 
compared to CSs.  
In general, FEP patients had significantly thinner cortex compared to CSs in 
two clusters in the left superior frontal (size = 1283 mm2 and size = 1193 mm2, 
respectively) and in the same region in the right superior frontal gyrus (size = 
5158 mm2). In contrast, FEP patients had significantly increased CTh in the left 
temporal pole (size = 1051 mm2) and in two areas of the right hemisphere: 
precentral (size = 1371 mm2) and temporal region (size = 1107 mm2). FEP 
patients had an increased CA in the left middlefrontal (size = 1055 mm2) and in 
the right occipito-parietal (size = 2359 mm2) anatomical area. 
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Figure 6. Statistical maps of right and left hemispheres lateral and medial views 
demonstrating significant cortical thickness (a) and cortical area (b) differences between 
FEP patients and CSs. The maps were produced from general linear models, com-
parisons were made controlling for the effects of age and gender. The p-values set at the 
FDR level 0.05 are presented in the colour bar (logaritmic value). Particular clusters, 
corresponding anatomical region names, cluster sizes, and Pcw values are presented in 
details in an Appendix (Table A1).  
 
 
 
6.3.3.2. The associations of neuropsychological tests scores  
with CTh and CA 
Neuropsychological tests scores were linked with brain morphological measures 
(CTh and CA) separately in the groups of FEP patients and CSs for associations 
and corresponding p values (Appendix, Table A2).  
Figure 7 (a, b) shows spatially distributed statistically significant CTh diffe-
rence maps indicating the contribution levels of brain regions identified by 
GLM analysis for each cognitive component.  
Within the FEP patients group, there were significant negative linear correla-
tions between CTh and IED reversal learning scores, indicating that worse per-
formance was related to cortical thinning in the left fusiform, superior frontal, 
isthmus cingulate and rostral middle frontal as well as right superior frontal and 
posterior cingulate regions. The same trend emerged in both groups between 
CTh and SWM strategy and SWM errors scores, demonstrating associations of 
poor spatial working memory manipulation and strategy usage with widespread 
bilateral cortical thinning, predominantly in clusters which contained voxels 
from frontal, temporal, parietal, and cingulate gyruses. Most of these as-
sociations were also observed in the CSs. We also observed a significant 
positive correlation between better performance of the spatial planning test 
(SOC) and bilaterally thicker cortex of temporal gyrus clusters, though only in 
the CSs group. In contrast, sustained vigilance task (RVP) scores correlated 
positively with left hemisphere cingulate cortex parameters within the FEP 
patients group. Associations between CTh and spatial working memory task 
(SSP) scores were also observed, but did not survive corrections of multiple 
comparisons in either of the groups.  
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Figure 7. Statistical maps of right and left hemispheres lateral and medial views of 
partial correlations of cortical thickness with neuropsychological tests scores among 
FEP patients (a) and CSs (b). The maps were produced from general linear models, 
comparisons were made controlling for the effects of age and gender. The p-values set 
at the FDR level 0.05 are presented in the colour bar (logaritmic value). Particular 
clusters, corresponding anatomical region names, cluster sizes, and Pcw values are pre-
sented in details in the Appendix (Table A2).  
IED, intra/extradimensional shift, SWM-errors, spatial working memory, errors 
score; SWM strategy, spatial working memory, strategy score; SOC, Stockings of 
Cambridge; RVP, rapid visual information processing.  
 
Figure 8 (c, d) shows spatial p-maps of linear correlations between CANTAB 
scores and CA in a vertex-wise manner.  
Among the FEP patients group, a diminished capability to perform set-
shifting tasks was significantly correlated with a smaller cortical area of the left 
frontal hemisphere, and SWM strategy scores were significantly correlated with 
superior frontal and temporal pole clusters in the left hemisphere and a superior 
temporal cluster in the right hemisphere, indicating associations between poorer 
strategy usage (SWM strategy score) and smaller CA in these regions. The 
ability to retain spatial information and manipulate remembered items in 
working memory (SWM errors score) was significantly negatively correlated 
with temporal and frontal surface regions in the FEP patients group. A trend for 
similar correlations (lower performance, smaller CA) emerged among the CSs 
in the left superior and middlefrontal and superior parietal areas, as well as in 
the right hemisphere (clusters: pars triangularis and rostral middlefrontal). 
Working memory capacity was significantly negatively correlated with right 
hemisphere occipital areas for both groups. No significant CA parameter effects 
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were observed for the spatial planning and rapid visual information processing 
task after controlling for multiple comparisons.  
 
 
Figure 8. Statistical maps of right and left hemispheres lateral and medial views of 
partial correlations of cortical area with neuropsychological tests scores among first 
FEP patients (c) and CSs (d). The paramteres were derived from GLM, controlling for 
the effects of age and gender. The p-values set at the FDR level 0.05 are presented in 
the colour bar (logaritmic value). Particular clusters, corresponding anatomical region 
names, cluster sizes, and Pcw values are presented in details in the Appendix (Table A2).  
IED, intra/extradimensional shift, SWM-errors, spatial working memory, errors score; 
SWM strategy, spatial working memory, strategy score; SSP, spatial span.  
 
 
6.3.3.3. Between-group differences in the associations of CTh and  
CA and neuropsychological tests scores 
We previously demonstrated that several CTh and CA clusters’ morphological 
parameters were associated with cognitive performance indices in both groups, 
and partial conformity emerged across the groups. However, to provide more 
specified information about how brain morphological (CTh and CA) parameters 
differentially contribute to cognitive performance heterogeneity in FEP patients 
compared to CSs, we conducted additional analyses. The results of the group-
wise regression-analyses, where correlation coefficients derived from both 
group were contrasted, are in details demonstrated in the Appendix, Table A3.  
Topographical maps (Figure 9) show spatially distributed group differences 
in the correlations between CTh (a) /CA (b) and cognitive measures.  
FEP patients had significantly different cortical structure – cognitive func-
tion relationships compared to CSs, which primarily pertained to the frontal, 
temporal, and occipital lobes. The relationship of spatial planning (SOC) with 
CTh in the left enthorhinal and right middle temporal, temporal pole and 
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inferior parietal clusters as well as the relationship between the strategy usage 
(SWM strategy score) and right supramarginal cluster were significantly weaker 
in FEP patients. 
 
 
 
Figure 9. Statistical maps of right and left hemispheres lateral and medial views of 
partial correlations differences of cortical thickness (a) and cortical area (b) with neuro-
psychological tests scores in FEP patients compared to CSs. Comparisons of FEP 
patients versus CSs brain-cognition relationship differences are taken from the GLM 
analysis. All comparisons were made controlling for the effects of age and gender. 
Significance is presented on a logaritmic (p-value) scale (p < 0.05, false discovery rate 
corrected), red–yellow indicates clusters where CANTAB test score-thickness (a) / -area 
(b) relationships are significantly stronger for the FEP patients; blue indicates clusters 
where the CANTAB test score-thickness (a) / -area (b) relationships are significantly 
weaker for the FEP patients. Particular clusters, corresponding anatomical brain region 
names, cluster sizes, and Pcw values are presented in details in the Appendix (Table A3). 
IED, intra/extradimensional shift, SOC, Stockings of Cambridge; SWM-errors, spatial 
working memory, errors score; SWM strategy, spatial working memory, strategy score; 
RVP, rapid visual information processing. 
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The relationship of spatial planning (SOC) with CTh in the left enthorhinal and 
right middle temporal, temporal pole and inferior parietal clusters as well as the 
relationship between the strategy usage (SWM strategy score) and right supra-
marginal cluster were significantly weaker in FEP patients. In contrast, FEP 
patients demonstrated statistically significantly stronger relationship between 
working memory manipulation component (SWM errors) and CTh in the right 
paracentral cluster as well as between rapid visual information processing 
(RVP) and CTh in the right lingual cluster. There were also group differences in 
CA-cognition correlations for the set-shifting task (IED), with FEP patients 
having a statistically significant weaker association between test scores and CA 
in the left pars triangularis cluster as well as a significantly stronger relationship 
pattern between spatial planning (SOC) and CA in the right lateral occipital 
cluster.  
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7. DISCUSSION  
The studies comprising the present thesis focus on characterizing the basic 
cognitive structure and profile of patients with FEP, emphasizing the view that 
cognitive deficit is a feature of the disease that has a neuroanatomical signature. 
Moreover, the present evidence suggests that there are broad as well as specific 
psychotic disorder-related deficits in different cognitive domains, which con-
verge with the correlations of these domains with brain’s morphological fea-
tures. Furthermore, our results provide confirmatory evidence that there is 
relative stability in cognitive functioning over a six-month period among FEP 
patients and that there are relationships between clinical symptoms as well as 
demographic characteristics and cognition. In addition, our findings support the 
hypothesis of independence of self-perceived cognitive functioning from 
objective neuropsychological deficits in FEP patients.  
Below is a detailed account of the implications of our findings. 
 
 
7.1.  Cognitive deficit as a core feature in first-episode 
psychosis (Paper I) 
The objectives of the study presented in Paper I were to characterize the struc-
ture of the cognitive functioning as well as the cognitive performance profile 
and overall magnitude of cognitive impairment of FEP patients compared to 
healthy peers of similar age measured by a computer-based comprehensive 
cognitive test battery (i.e. PRM, SRM, PAL, IED, SOC, SSP, SWM, and RVP) 
derived from CANTAB.   
Traditional neuropsychological batteries typically contain a heterogeneous 
set of tests, and many tests may not fit neatly into a single domain (Keefe & 
Harvey 2012). Therefore, the first aim of this study was to define the latent 
structure of the test battery currently being used.  
There are two techniques (i.e. principal component analysis and exploratory 
factor analysis) which can be used to examine which combinations of features 
are appropriate for data, and for reducing the dimensionality of features. With 
regard to our sample composition (i.e. FEP patients and healthy subjects) and 
selected CANTAB tests scores, previous literature did not provide a well-
grounded theory to base our analysis on. Under this certain circumstance, it is 
suggested to use PCA to reduce the number of variables whereas retaining as 
much of the original variance as possible (Conway & Huffcutt 2003). We relied 
on PCA as it is based on all of the variance in test scores rather than only tests' 
common variance, being thereby less hypothesis-free.  
According to the results of the exploratory PCA and subsequent single group 
CFA we found that the selected CANTAB tests may group into two different 
cognitive factors in both FEP patients and healthy people. Whereas two 
relatively distinct factors (i.e. “attention/memory” and “executive factor”) 
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appeared to be a tenable solution among controls, a single broad ability factor 
however was clearly evident among patients. Our results are in agreement with 
previous studies (Gladsjo et al. 2004; Dickinson et al. 2006; Burton et al. 2013) 
which demonstrated that inter-correlations of cognitive domains are higher for 
FEP patients than CSs. In other words, patients appeared to rely more heavily 
on general cognitive ability than on individual cognitive processes; or put diffe-
rently, when FEP-related cognitive decline sets in, it tends to be pervasive and 
pull along all cognitive skills. In particular, the more homogeneous cognitive 
profile of patients may reflect a similar impairment of cognitive skills resulting 
from disease-related or disease-preceding processes. Furthermore, we replicated 
the findings of a confirmatory factor analysis (CFA) of FEP patients cognitive 
test scores (Leeson et al. 2009a), revealing that cognitive functioning in control 
and patient groups could not be explained by similar measurement models.  
Once the latent structures were defined by a sequence of factor analytic 
models, we extended the analysis by formally testing for the presence or lack of 
MI of the constructs across subgroups. MI in psychology is obtained when the 
relations between observed scores and latent constructs are identical across 
relevant groups (Drasgow 1984). However, because measuring instruments are 
often group-specific in the way they operate, baseline models could not 
expected to be identical across groups. 
Our results indicate that the cognitive differences between FEP patients and 
CSs may not be limited to quantitative (i.e. nomothetic) variability, but there 
may also be qualitative (i.e. structural) differences. Regardless of the MGCFA 
results which indicated that the cognitive domains could be constructed in the 
same way in controls and patients (configural invariance held for both one and 
two- trait models), the nature of the relationships between observed test scores 
and their purported underlying constructs tended to be dissimilar. This sug-
gested that the latent factor scores were not comparable because observed test 
scores were probably influenced by characteristics other than the latent ability. 
In other words, patients' cognitive profiles were less diverse than those of CSs 
and this may be a result of neurodevelopmental or psychosis-related processes 
which impacting cognitive domains in particular ways.  
Results of this study emphasizes the importance of establishing MI, which 
can cover nuanced group differences that might otherwise remain undetected.  
In addition, our results reinforce the view that there is broad cognitive deficit 
associated with FEP. At the group level patients exhibited worse performance 
than CSs on all measured CANTAB subtest scores, indicating substantial 
cognitive impairment. According to our results, impairments were present in 
several aspects of attentional functioning (including set shifting and sustained 
attention), speed of processing information, working memory (including storage 
and manipulation), visual and episodic memory, and executive functioning. 
Executive functioning, set shifting, and processing speed emerged as the most 
affected cognitive domains, followed by working memory, spatial memory, 
episodic memory, and visual recognition memory, in patients’ group. Perfor-
mance differences between FEP patients and CSs remained significant even 
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after adjusting for years of education, age and gender, which is consistent with a 
number of others studies (Heinrichs & Zakzanis 1998; Townsend & Norman 
2004; Dickinson et al. 2007).  
Our findings provide supportive evidence for the qualitative and quantitative 
cognitive functioning impairment as core feature of many patients with chronic 
psychotic disorder as it is present already at the early stage of the disease. 
 
 
7.2.  The course of cognitive functioning after  
first-episode of psychosis (Paper II) 
The second study provides comprehensive cognitive functionality characteri-
zation of patients at the early stage after the FEP in terms of rank-order and 
mean-level stabilities as well as MI.  
Measurement of cognitive functions at baseline and at six month period 
allowed an evaluation of their variation over time and their association with 
clinical and demographic indicators. In addition, correspondence between 
subjective and objective cognitive functioning was evaluated.  
One can suppose that cognitive abilities demonstrate highly stable course 
during the six month period in each individual and distinguish him or her from 
other individuals. Otherwise, cognitive abilities may be also subjects to change.  
Detecting change in individual patient’s neuropsychological performances 
requires the use of appropriate methods. There are two specific types of change 
over time one can focus on: rank-order change (i.e. change in an individual’s 
cognitive performance relative to other individuals’) and mean-level change 
(i.e. changes in average performance over time). The two are independent of 
each other. For example, perfect rank-order stability may characterize groups 
with substantial mean-level change, because individuals often change in the 
same way.  
There is limited information available about the stability of the CANTAB 
cognitive battery tests for different groups of patients, and especially for 
patients with FEP.  
In terms of mean-level trends, our results appeared to show that spatial re-
cognition (PRM) and episodic memory (PAL) declined over a six month period. 
In contrast, mental flexibility (IED), executive functioning (SOC), manipulation 
with items in one’s working memory (SWM), and information processing speed 
(RVP) seemed to improve. We did not detect any evidence for changes in 
pattern recognition memory (PRM) or working memory capacity (SSP). Our 
results tend to corroborate previous suggestions (Censits et al. 1997; Rund 
1998; Heaton et al. 2001) that there is no broad progression of cognitive deficits 
during the initial stages of chronic psychotic disorders. This supports the 
hypothesis of a primary neurodevelopmental deficit (Weinberger 1987; Murray 
& Lewis 1988; Bora 2015). 
Moreover, previous researchers have also demonstrated cognitive improve-
ment in CSs and FEP patients (Nopoulos et al. 1994; Hoff et al. 2005; 
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Rodríguez-Sánchez et al. 2008). However, one should consider the cognitive 
process being measured and how this may change with repeated assessments 
(Heilbronner et al. 2010). Measures of executive functioning generally show 
lower mean-level consistency. Notably, tests of executive function (IED, SOC, 
SWM) rely considerably on novelty. Thus, cognitive improvements in FEP 
patients during the early course of the disease may be related to a practice 
effect, a common process shared by CSs, and therefore increased mean change 
levels may not reflect real cognitive improvement, but rather stability or deficit 
(Goldberg et al. 2007).  
In terms of the paired association learning test (PAL), our results are in line 
with previous studies that showed a decline in this particular cognitive function 
during the early phases of chronic psychotic disorder (Bilder et al. 1992; Hoff et 
al. 1999). In contrast, studies of FEP patients that have used memory and 
learning subtests from the MATRICS (Measurement and Treatment Research to 
Improve Cognition in Schizophrenia) Cognitive Consensus Battery (Nuechter-
lein et al. 2004) have detected improvements in the performance of visual 
learning and working memory tests over a six month period (Olivier et al. 2015) 
or stable mean-levels over a year (Benoit et al. 2014). We speculated that in-
consistent findings between these studies could be owing to them having patient 
groups with different symptom severities, using a different cognitive func-
tioning measurement methodology, and employing different statistical methods.  
The results concerning our analyses of the rank-order coefficients revealed 
high stability (r = 0.80 to 0.94) in the rank ordering of patients over time. 
Former studies using subtests from CANTAB battery have reported moderate to 
high (r = 0.40–0.84) stability indices over four weeks to three years for patients’ 
samples with schizophrenia or FEP (Leeson et al. 2009b; Barnett et al. 2010). 
However, it is important to remember that test-retest correlations can vary 
depending on the sample assessed, and the amount of time between test and 
retest (shorter retest intervals lead to higher reliability coefficients) (Duff 2012).  
In longitudinal models, a high degree of rank-order stability of a charac-
teristic indicates either that individuals did not change much over time or that 
individuals changed over time, but in more or less the same way (i.e. everyone 
decreased or increased to the same extent). Therefore, a high rank order stability 
limits our possibility to identify factors in which individuals differ and that 
could have an influence on the characteristics.  
The rank-order stability estimates can be also seen as the lower-bound 
reliability estimates of the CANTAB subtests: their actual reliability can only be 
equal or higher, because the observed stability may have also reflected real 
change over time.  
The magnitude of the observed stability estimates from our study supports 
the CANTAB as a reliable instrument to assess cognitive functioning in FEP 
patients. 
In mental health care, both clinical and scientific decisions for patients’ 
cognitive functioning are frequently based on within-subject comparisons of 
neuropsychological test scores of the same battery at different points in time. To 
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establish the validity of test score comparisons over time, longitudinal MI 
should be established.  
To the best of our knowledge, this is the first report to investigate the struc-
ture of the CANTAB tests ICSs (i.e. deviations from individual’s predicted 
scores at follow-up) among FEP patients over six-months period. In order to see 
which patterns would emerge, PCA was performed. The first dimension iden-
tified by the PCA was assumed to reflect an underlying broad cognitive ability 
trait.  
The plausibility of the model was estimated using CFA, which confirmed 
that the empirical model in which measures of CANTAB subtests were loaded 
on one broad ability domain demonstrated an excellent fit for the data. The 
replicability of the cognitive traits structure between the two testing occasions 
was evaluated using multi-group (groups represented occasions) confirmatory 
factor analysis. 
Employing CFA, we tested whether the parameters of the factor model are 
different across consecutive measurements, similarly to how MI was tested 
across FEP patients and CSs.  
Inspection of the goodness-of-fit statistics for the one-factor model of FEP 
patients indicated the model was a reliable representation of the data at the two 
time points. These results are consistent with our previous study (Haring et al. 
2015b), which examined the potential relationships of an identical set of 
variables between CSs and FEP patient samples. This suggested that, in contrast 
to CSs, a broad latent ability factor model was the most appropriate represen-
tation of the relationships between the neuropsychological variables among FEP 
patients. This is consistent with the findings in previous studies that used a 
different kind of neuropsychological tests (Censits et al. 1997; Dickinson et al. 
2006) or the same test battery (Leeson et al. 2009a). The finding of invariance 
of the factor loadings, provides empirical evidence to support the assumption 
that test scores measured an invariant psychological trait, and that latent factors 
had the same meaning after six month among FEP patients. However, the 
observed scores’ intercepts were not invariant between the two assessments, and 
misfit of scalar invariance suggests that comparisons of the factor means should 
be interpreted with caution.  
Overall, these findings suggest that when the FEP patients’ neuropsycho-
logical performance is compared on a timeline, CANTAB subtest scores should 
be used. 
Although heterogeneity in terms of mean-level change and high rank-order 
stability emerged over a six month period, it is of theoretical, practical, and 
clinical importance to examine how individuals differed from each other, and 
what variables, if any, could explain such individual differences.  
Of the demographic and other characteristics taken into account, age and 
education seemed to have by far the most important impact on cognitive 
performance. Furthermore, one of the most consistent finding is that men are 
younger than women at the onset of a chronic psychotic disorder (Eranti et al. 
2013). In the present study, although men’s mean age at onset was indeed lower 
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compared to women, the difference was not significant. According to our 
results, being younger had a significant correlation with the paired associate 
learning subtest change scores (PAL), which is consistent with previous results 
among healthy control subjects (desRosiers & Ivison 1988). A longer time in 
education had a correlation with performance change at the processing speed 
task (RVP).  
Gender differences in cognitive functioning are well known among healthy 
individuals. In general, women tend to perform better than men at tasks mea-
suring verbal abilities, whereas the opposite is the case regarding visuospatial 
skills (Halari et al. 2005). However, a recent review by Hyde (2016) suggests 
that males and females are quite similar in terms of most, but not all cognitive 
variables, and gender differences can vary substantially in magnitude with ages 
and the context in which the measurements occur. Gender differences in 
cognitive functioning among patients with FEP are a controversial issue (Albus 
et al. 1997; Hoff et al. 1998; Ittig et al. 2015). In this study, men made less 
reverse errors at the set-shifting task (IED), had better spatial executive functio-
nality (SOC), higher spatial span length (SSP), and used strategies (SWM) more 
effectively than women. Regarding visual (PRM) and spatial (SRM) recognition 
memory and paired associate learning (PAL), as well as information processing 
(RVP), men and women performed equally. A similar trend in gender diffe-
rences was traceable among the ICSs of the tests (that is, changes in scores over 
time as opposed to their levels at baseline). It is worth mentioning that we used 
computerized tests that measure performance based on visuospatial abilities, 
and our findings on gender differences are in accordance with previous reports 
of the generally better performance of male patients in these domains (Albus et 
al. 1997). Among patients with schizophrenia, Perlick et al. (1992) found that 
women had lower performance at attention tasks, and Roesch-Ely et al. (2009) 
demonstrated that women scored lower than men on executive functioning, and 
working memory tasks. However, some previous literature has reported lower 
overall cognitive performance among males with schizophrenia (Goldstein 
1988; Seidman et al. 1997) or a lack of gender difference among schizophrenia, 
and FEP patients (Hoff et al. 1998; Ittig et al. 2015).  
There may be several factors that contribute to the heterogeneity of the 
results of these studies. For example, men and women may vary in their symp-
toms of expression over the course of illness and in response to treatment, and 
differences may be related to the selected study sample (e.g. patients with 
chronic illness or FEP, and early- or late-onset schizophrenia patients) (Mend-
rek & Mancini-Marïe 2016).  
In addition, we suspected that aspects of psychopathology might differen-
tially account for any differences in cognitive functioning between the two test 
occasions.  
The associations between illness-dependent symptom dimensions and cogni-
tive functioning have been widely studied, and the relationship between symp-
tom dimensions and cognitive domains varies across groups of symptoms. 
Studies have demonstrated that negative symptoms and disorganization are 
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associated with cognitive functions, with more severe symptoms related to 
poorer cognitive performance (Harvey 2013). Overall, findings suggest that 
cognition is more closely associated with negative than positive symptoms 
(Heinrichs & Zakzanis 1998; Nieuwenstein et al. 2001).  
It is worth emphasizing that the levels of changes in symptom dimensions 
severity were calculated and used in the further analysis in our study. According 
to our results, patients’ cognitive functioning change across consecutive mea-
surements could not be attributed to changes in their negative symptoms. 
Consistent with our finding, Bell and Mishara (2006) demonstrated that changes 
in negative symptoms did not predict changes in cognition, and concluded that 
negative symptoms could not directly cause cognitive impairment or vice versa.  
With regard to the relationships between positive symptoms and cognitive 
performance, the literature is less consistent. The meta-analytical review of 
Dominguez et al. (2009), suggested only a slight negative correlation occurs 
between processing speed and positive symptoms among patients with 
schizophrenia, whereas recent works by Olivier et al. (2015) and Trampush et 
al. (2015) found that a decline in the positive symptom dimension score of FEP 
patients was related to improvements in speed of processing, attention/ 
vigilance, working memory, verbal memory, verbal and visual learning, as well 
as reasoning and problem solving tasks. Our results revealed that improved 
performances at spatial working memory and processing speed tests, were 
associated with diminished positive symptom scores.  
In addition, we demonstrated clinically meaningful and statistically signifi-
cant correlations between AP dose and BPRS ratings. The results indicated that 
patients with more severe treatment-refractory symptoms, received higher doses 
during the both assessment. During the six month period as patients continued 
to recover, psychopathology scores decreased, and as such AP doses were 
gradually reduced. We found potential impact of changes to CPZ equivalent 
dosage on frontal lobe functionality: reduced doses appeared to mediate an im-
provement in working memory capacity (SSP span length), as well as change 
towards enhanced executive functioning (SOC problem solving). Previously, 
Sota and Heinrich (2003) also found that CPZ equivalent dose was negatively 
related to learning and recall abilities. For that reasons, the suggestion was 
made for clinicians to carefully consider changing drug doses in terms of 
quantity and or frequency it is taken, when psychopathology severity has 
declined, and use a lowest-dose strategy whenever possible. However, an indi-
vidual approach is recommended whenever any antipsychotic dosage change is 
considered. 
In addition, our data highlighted the need to evaluate additionally patients’ 
subjective experiences of cognitive functioning to provide more comprehensive 
view about the clinically important dimension (i.e. cognitive impairment) of the 
disorder. There is little empirical information with respect to the subjective 
cognitive complaints in relation to objective neuropsychological test perfor-
mance among healthy population compared to patients with chronic psychotic 
disorder. However, the relationship tends to be stronger for the CSs (r = 0.31,  
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p = 0.05), and nonsignificant for patients with schizophrenia (Medalia et al. 
2008; Sellwood et al. 2013). Previous studies have demonstrated that self-
assessed cognitive dysfunction is also prevalent among patients with FEP 
(Moritz et al. 2000; Homayoun et al. 2011). Results of the present study are in 
line with others (van den Bosch & Rombouts 1998; Zanello & Huguelet 2001; 
Chang et al. 2015), in supporting the hypothesis of the independence of self-
perceived cognitive disturbances, from objectively measured cognitive impair-
ments, among FEP patients. 
In the literature, several explanations have been proposed for this discrepant 
finding, which is not unique for the FEP patients and which is often observed in 
clinical neuropsychology. Psychological factors (such as anxiety, depression, 
dysphoria, personality traits), as well as physical factors (such as fatigue, pain), 
can impact subjectively perceived cognitive functioning above and beyond 
neurolopsychologically determined cognitive status (Sweet 2000).  
Moreover, the findings suggests that patients’ subjective perceptions of their 
cognitive function have a different theoretical basis than objective indicators, as 
patients do not conceptualize their cognitive functioning in terms of distinct 
cognitive domains, as clinicians and neuropsychologists do (Stip et al. 2003). 
The domains assessed by neuropsychological tests may have little overlap with 
the everyday experience on which patients base their self-report. In the other 
words, the conditions under the neuropsychological tests are assessed may be 
different from real-life demands. During the neuropsychological testing patients 
are encouraged to do their best and cognitive tests attempt to assess subjects 
maximal level of functioning, whereas how subjects cope with daily life reflects 
their typical level of functioning (Salthouse 2012). Furthermore, patients may 
be able to perform well during a relatively short test period, but their daily 
functioning may be compromised and give rise to cognitive complaints. At the 
same time, neuropsychological tests may accentuate the existence of deficits, 
without affecting daily life functioning.  
Furthermore, the discrepancy may occur owing to variations in methodology 
(differences in the subjective cognitive scales employed) and study design. We 
used the SWN-K-E “Cognitive Functioning” subscale that comprises four 
simple statements about self-perceived cognitive functioning. This subscale did 
not seem to appropriately correspond to the specific cognitive test scores ob-
tained using the CANTAB. In addition, one possible explanation for the low 
inter-correlation between measurements might be the different nature of the 
evaluations. The CANTAB tests were all visually presented to subjects and high 
performance relied on visual information processing, whereas the subjectively 
perceived cognitive functioning items might refer to much broader indicators 
including among others verbal and arithmetical abilities, as well as semantic 
processing.  
However, both methods (SWN-K and CANTAB subtests) have been vali-
dated among psychotic populations (Elliott et al. 1995; Naber et al. 2001; Joyce 
et al. 2005; Leeson et al. 2009a; Haring et al. 2013, 2015b).  
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It could also be argued that awareness of one’s own cognitive deficits could 
be affected by awareness of one’s condition as a mentally ill person, and 
schizophrenia is frequently accompanied by a lack of insight (Pini et al. 2001). 
However, the literature suggest that subjective and objective cognitive tests 
might have unique contributions, and thus both should be implemented to give a 
broader perspective about a patient’s cognitive functioning to determine 
appropriate clinical practice regarding assessment and management of cognitive 
problems. 
 
 
7.3. Brain morphological correlates to  
cognitive functioning (Paper III)  
The third part of the thesis focused on brain MRI correlates of cognitive func-
tion in patients with FEP and CSs. Our aims were to investigate how the cog-
nitive deficits of FEP patients compared to CSs are reflected in both CTh and 
CA morphological parameters.  
To attain our main objective, we first replicated the earlier findings (Bilder et 
al. 2000) that cognitive impairment in FEP patients is substantial, amounting 
from moderate to high effect size, and cuts across various neuropsychological 
measures (i.e. set shifting, executive functioning, working memory, spatial 
working memory, and information processing tasks).  
Thereafter, differences in CTh and CA morphological parameters were eva-
luated between the FEP patients and CSs, and our analysis revealed significant 
bilaterally reduced CTh in the middle- and superior-frontal and left anterior 
cingulate cortex areas of FEP patients. These findings are in line with studies by 
Narr et al. (2005) and Fornito et al. (2008). However, our finding of thickened 
clusters of cortex in the left temporal pole and right middle and inferior tem-
poral cortex in FEP patients compared to CSs contradict previous research, 
which has found reductions in left and right temporal poles or no morphological 
changes at all in these brain regions (Vita et al. 2006; Roiz-Santiáñez et al. 
2010). We suggest that variations in quantitative assessment techniques, as well 
as use of different covariates and significance thresholds might explain these 
inconsistencies, in addition to either finding reflecting type 1 error. Previously, 
Takayanagi et al. (2011) used the automated surface-based approach provided 
by FreeSurfer, and demonstrated CTh reduction in 52 FEP patients compared to 
40 CSs which was most prominent in the prefrontal and temporal cortices (the 
between-group comparison consisted of the mean thickness of the region of 
interest). In our study, cortical reconstructions were performed using a similar 
methodological approach, except that we used an entire cortex surface-based 
cluster analysis. Using the same methodology (as we did), Ansell et al. (2015) 
demonstrated that a non-affective FEP patients group (n = 27) exhibited pro-
nounced cortical thinning compared to CSs (n = 27) in frontal regions and did 
not find overlapping patterns of reduced cortical thickness in the left temporal 
pole or in the inferior temporal gyrus. Furthermore, they characterized the diffe-
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rential effect of first and second generation antipsychotic (FGA and SGA) 
medication on CTh parameters and found that patients treated with SGA dis-
played increased CTh in frontoparietal regions compared to patients treated 
with FGA, and that the SGA group had higher CTh in the pre- and post-central 
sulcus than the CS group. Our notably larger study, in which all the patients  
(n = 63) were treated with SGA, also found increased thickness in the right 
precentral cluster.  
The reasons for the increased cortex thickness clusters among the FEP 
patients found in our study are not entirely clear. One can assume that increased 
proinflammatory status might represent a compensatory effect during the early 
stage of the disease. Doorduin et al. (2009) and van Berckel et al. (2008) 
reported increased activation of microglia cells, especially in the temporal 
lobes, among patients with early-stage schizophrenia compared with CSs. 
Furthermore, astrocytes can be activated by proinflammatory cytokines (e.g. 
interleukins) and growth factors (e.g. epidermal growth factor) that may lead to 
cellular hypertrophy and astrocyte proliferation, which could increase cortical 
thickness (Liberto et al. 2004). We have demonstrated previously, using the 
partially same participants, that antipsychotic-naïve FEP patients exhibit altera-
tions in cytokine and growth factor levels (Haring et al. 2015a). The CTh in-
crease in the temporal region that we report in the current study, may be 
particularly relevant to the processes one can see during the very early stage of 
the disease. 
Furthermore, our results suggesting enlarged surface area clusters in the left 
middlefrontal and right occipito-parietal areas, and thus did not replicate pre-
vious findings of surface area reduction or no change in these cortical para-
meters in FEP patients (Crespo-Facorro et al. 2011). Possible explanations for 
such heterogeneity among results are the differences in sample sizes and or 
composition; our sample was relatively large among the studies of the kind and 
it was also gender-balanced. For example, female patients with schizophrenia 
are underrepresented in the literature (Tamminga 1997), whereas males and 
females were equally represented in both groups of the present study.  
Similarly to the present findings, previous structural MRI studies have sug-
gested that FEP patients brain volume loss, although widespread, is not homo-
geneous (Keshavan et al. 2005; Vita et al. 2006), antipsychotic treatment may 
have impact on brain tissue (Keshavan et al. 1998) and chronic psychotic 
disorder itself demonstrate a non-static nature (Shenton et al. 2001). It has been 
argued that cortical thinning (Rimol et al. 2012) or surface area reduction 
(Sanabria-Diaz et al. 2010) is the most important factor in volume reduction, 
with some suggestion that cortical folding differences could account for the 
some of the regional differences (Palaniyappan et al. 2011). Neuropathological 
studies suggest that the cellular changes associated with these anatomical pro-
perties affect diverse tissue compartments in a regionally heterogeneous way. 
Cellular shrinkage, reduction in dendritic arborization, an increase in myeli-
nation of GM and decreased interneuronal neuropil in the prefrontal cortices, 
and disruptions in WM bundles connecting cortical association areas, are the 
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pathological mechanisms most likely related to cortical thinning and impaired 
connectivity and functionality (Selemon et al. 1998; Selemon & Goldman-
Rakic 1999; Casanova et al. 2005).  
Hence, it may be that the measurements of CA and CTh recorded in this 
study reflect structural aspects other than the columnar organization of the 
cortex. However, these findings may indicate that changes in the anatomical 
properties of the cortical mantle underlie the GM volume variations and that it 
is necessary to explore CTh and CA separately to better understand the neuro-
biological mechanisms associated with brain abnormalities among FEP patients.  
In addition, data presented in this thesis provide insight into the relationships 
similarities and differences of the FEP patients and CSs neurocognitive perfor-
mance using the CANTAB tests scores with CTh and CA parameters. A number 
of studies have previously examined correlations between cognitive perfor-
mance and cortical volume, CTh and or CA in FEP patients (Salgado-Pineda et 
al. 2003; Minatogawa-Chang et al. 2009; Gutiérrez-Galve et al. 2010; Crespo-
Facorro et al. 2011; Hatton et al. 2012, 2013). With respect to the localized 
regions of the cerebral cortex where thickness or area correlates with cognitive 
performance, the findings of the present study are consistent with these of 
above-mentioned studies, indicating that a diffuse pattern of asymmetrically 
reduced CTh and CA (predominantly encompassing frontal, temporal, parietal 
and cingulate cortices) was correlated with lower attentional set-shifting (IED 
error score), a diminished capability to manipulate items in spatial working 
memory (SWM error score) and strategy usages (SWM ineffective strategy 
usage), and a thicker left cingulate cortex was correlated with better information 
processing (RVP score or sensitivity for detecting sequences) among the FEP 
patient group. In addition, in the current study, an inverse correlation between 
working memory capacity (SSP) and CA was observed for both groups in the 
pericalcarine/lingual/occipital region, with a thinner cortex being associated 
with better performance. Findings such as this require further investigation with 
larger samples of subjects.  
In general terms, although the association patterns somewhat overlapped, 
there was some heterogeneity between the groups and bilateral asymmetry in 
both groups. Previous studies have also shown that some brain structure/neuro-
cognitive associations tend to be specific to FEP patients (Toulopoulou et al. 
2004; Cocchi et al. 2009; Minatogawa-Chang et al. 2009; Crespo-Facorro et al. 
2011; Ehrlich et al. 2012; Hatton et al. 2013) and our study provides comple-
mentary findings of neuropsychological function-brain structure association 
alterations in FEP patients compared to CSs which may be due to a mixture of 
genetic, neurodevelopmental and environmental effects. Alterations in structural 
measurements suggest disturbances in brain maturation, supporting the neuro-
developmental hypothesis of schizophrenia pathophysiology (Weinberger 1987; 
Murray & Lewis 1988). Moreover, it has been argued that structural and 
functional changes seen in patients with chronic psychotic disorder may be a 
consequence of disturbed brain regenerative capacities (Falkai et al. 2015), 
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which may be incorporated with epigenetic dysregulation, which is involved in 
neuronal plasticity mechanisms (Hasan et al. 2013). 
Our results agree with the suggestion that neuroanatomical/cognitive ability 
alterations are not limited to individual brain regions, but rather affect wider 
neural systems (Friston 1998) and that besides the prefrontal dysfunction, other 
brain regions may be invoked in a compensatory response to cognitive demands 
in FEP patients, which is similar to what has been suggested for schizophrenia 
patients (Tan et al. 2007).  
However, there is a growing body of evidence suggesting that a disturbance 
in connectivity between different brain regions, rather than abnormalities within 
the separate regions themselves, are responsible for the clinical symptoms and 
cognitive dysfunctions observed in the pathophysiology of the disorder (Friston 
1998; Bassett et al. 2008; Stephan et al. 2009), and according to the results of 
the current study, we hypothesize that the cortical parameters that contribute to 
variability in the functions of sustained attention, spatial working memory, 
spatial planning and set-shifting mental flexibility in healthy individuals may be 
abnormal in FEP patients.  
Our study strengthens the evidence for an altered relationship between 
disease-related changes in brain morphology and clinically important cognitive 
difficulties in FEP patients.  
 
 
7.4. Methodological issues and limitations  
Before summarizing the results coming out of this thesis, the following metho-
dological issues, participant samples characteristics and limitations should be 
considered.  
First, the recruitment of subjects was based on opportunity rather than 
random sampling. The clinical sample was restricted to a group of patients that 
were clinically stable and willing to participate in the testing. Subjects in the 
control group came from a sub-population and results may not be extrapolatable 
to the general Estonian populace. Our findings may thus not reflect the overall 
cognitive characteristics of patients with FEP in Estonia or beyond. It must be 
noted, however, that the sample was relatively large in the context of typical 
sample sizes in the research area. 
Second, the recruited patients were virtually heterogeneous in terms of 
diagnosis, medication, and duration of untreated illness – something which is 
difficult to avoid among any sample of FEP patients. Nevertheless, patients 
were at the early stage of the chronic psychotic disorder which allowed to 
diminish confounding effects of chronic condition and/or continuous treatment 
impact. Potentially, antipsychotic medications could be influencing cognitive 
function, although how and to which extent is still entirely unknown.  
Whereas all atypical antipsychotics share serotonin/dopamine antagonism, 
they vary notably in their affinity at other receptors, including cholinergic, 
muscarinergic, serotonergic, adrenergic, and histaminergic receptors with a mix 
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of agonist and antagonist effects (Stahl 2013). As most neurotransmitter activity 
is regulated by multiple other systems, it is hard to distinctly estimate the 
specific effects of particular antipsychotic drugs. Furthermore, because of the 
naturalistic study design some of the patients received additionally mood stabi-
lizers or antidepressants and patients were treated with various antipsychotic 
medications and when clinical need occured changes were made in doses or 
specific active substance selections. In addition, majority of the patients were 
engaged in psychotherapeutic intervention. These conditions were not taken 
under control in the analyses. 
Moreover, we did not exclude participants with comorbid conditions, for 
example cannabis use in the previous anamnesis as attempt was made to 
investigate natural cohort of patients with FEP. 
Third, to reliably identify the profile and pattern of cognitive deficit in FEP 
patients, it is essential to have a comprehensive battery of neuropsychological 
tests that is sensitive to specific as well as general cognitive impairment. 
However, the findings of differential deficits should be interpreted in the con-
text of the psychometric limitations of the neuropsychological tests (i.e. their 
ability to measure specific cognitive processes) (Krabbendam & Jolles 2002). 
Nevertheless, the use of traditional clinical neuropsychological measures of 
cognition among patients with psychotic disorder has the advantages because of 
normative data and standardized administration, and remains the standard for 
cognitive assessment in clinical practice. In addition, when generalizing the 
findings over studies, one should be aware that different studies used different 
neuropsychological tests to assess the same cognitive function. It is noteworthy 
that there is a need to differentiate studies that used general ability scores versus 
individual neuropsychological test scores when comparing FEP patients to CSs, 
over time or to brain morphological parameters.  
Forth, the current study did not assess the premorbid cognitive functioning 
of the patients as we lacked properly adapted existing instruments in Estonian. 
Of course, a proper assessment of pre-morbid cognitive abilities would require 
early testing of the general population as it is not known at that point who will 
develop a psychotic disorder.  
Fifth, we did not control intra-individual factors that may influence testing or 
test-retest consistency, such as poor motivation, fatigue or cigarette smoking 
prior to the CANTAB test sessions.  
Sixth, several statistical issues associated with conducted analysis should be 
mentioned. The limited (in absolute terms) sample size may have reduced 
statistical power for the analyses. We admit that patients were at the early stages 
of the illness when cognitive performance was evaluated, so results are not 
necessarily generalizable for different follow-up periods. In addition, we 
adopted the vertex by vertex whole brain analysis in order to assess group 
differences in the CTh and CA parameters and the extent to which cognitive 
performance scores were related to brain morphology across GM tissue. To 
establish significant differences cluster-defining threshold (thresholding criteria 
0.05) and FDR criteria (i.e. correction for multiple comparisons, p < 0.05) were 
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implemented. However, it is important to note that above-mentioned statistical 
methods could not avoid entirely false positive results. In addition, as we 
correlated cognitive performance scores (which may have state-related nature) 
with brain structure parameters (which are rather trait-related variables) our 
findings might be inclined to false negative results, as cognitive performance is 
more dynamic than brain structural changes.  
Finally, we reported linear correlations between the cortical morphological 
parameters and cognitive functioning, but it is important to acknowledge the 
possibility that such associations may not follow a linear relationship (Hartberg 
et al. 2010; Hatton et al. 2012). Furthermore, we should be aware of the 
inescapable fact that correlational research does not tell us that there is causality 
between variables, but rather that they are somehow related. It should also be 
emphasized that measurements of CTh or CA did not directly reflect functional 
activation during task performance. Nonetheless, if a set of cortical regions 
show significant thinning and it is known that those areas are interconnected 
within the particular brain cognitive network, it is reasonable to conclude that 
certain cortical layers and cell types are relevant for particular cognitive 
function (Makris et al. 2006).  
Despite these limitations, our research has some strengths, mainly related to 
the natural FEP patients sample (we have gathered a well characterized study 
material on a group of patients that is challenging to include in research), the 
longitudinal design used to evaluate changes in cognitive functioning over time, 
and the low level of drop-outs by the follow-up period.  
 
 
7.5. Clinical relevance 
Despite the potential limitations discussed above, we believe the present thesis 
offers interesting results that are useful in everyday psychiatric practice.  
Cognitive impairment is a core feature of schizophrenia, and the importance of 
neuropsychological assessment both in research and clinical practice cannot be 
overestimated. Our findings show, in line with earlier research, that there is 
evidence for a generalized cognitive deficit in FEP.  
Our findings have practical significance for the broader use of neuropsycho-
logical tests for assessing cognition at the early stage of psychotic disorder. 
According to our results we recommend that assessments which use CANTAB 
could not compare individual FEP patient’ and CSs in terms of their mean latent 
cognitive factors because the underlying structural relations among the 
cognitive tests were different between the groups (i.e. FEP patients vs. CSs) and 
within the group between two time point (i.e. baseline and follow-up testing 
occasion), the analyses should be restricted to differences in the subtests levels.  
Although no specific „neurocognitive profile“ exists for psychotic disorders 
(Mohamed et al. 1999; Bilder et al. 2000) and the assessment may not be 
helpful for the diagnosis, it has significant contributions to understanding 
individual patient’ cognitive functioning and the course of the impairment, be-
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cause it has been suggested that different patterns of neurocognitive dysfunction 
could contribute to the heterogeneity of the disease and its variable functional 
outcome (Holthausen et al. 2002).  
Among FEP patient particular attention should be paid to cognitive impair-
ment when defining the therapeutic strategy and rehabilitation programs.  
The controversial cognitive benefit of typical and atypical antipsychotics 
(Keefe et al. 2007) has led to the search for alternative pharmacological mecha-
nisms to enhance cognitive function (Keefe et al. 2013). Although potential 
pharmacological targets have been identified (i.e. cholinergic, dopaminergic, 
GABA-ergic, glutamatergic agents, alpha-7 nicotinic receptor agonists), to date, 
however, no drug has been approved for this indication (Harvey 2013).  
In addition, cognitive remediation interventions have generated considerable 
interest as these methods are far less costly than pharmacologic treatment and 
are likely to be safer. This includes methods to train or restore cognitive 
function and compensatory techniques through modifying cognitive domains of 
attention, working memory, executive functioning as well as planning with the 
goal of durability and generalization (Wykes et al. 2011). Several studies and 
meta-analysis suggest that cognitive remediation produces small-to-medium 
effect size improvements in cognitive performance, and when combined with 
any psychiatric rehabilitation (e.g. supported employment, vocational rehabili-
tation and social skill training), also helps patients achieve better functional 
outcomes (McGurk et al. 2007b, 2007a; Wykes & Huddy 2009; Wykes et al. 
2011).  
 
7.6. Implications for further research 
We believe that our work has drawn attention to the need for further validation 
of the CANTAB on larger populations, through more longitudinal period, 
between patients groups with different disease duration and to investigate the 
stability of the structure of cognitive functioning among patients with chronic 
psychotic disorder cross-culturally.   
With regard to MRI study, our results support a viewpoint’s that brain GM 
alterations are an early feature of the pathogenesis of the chronic psychotic 
disorder. The mechanisms that underlie these alterations, the nature of these 
alterations and causal relationships between the brain morphology and cognitive 
functioning require further research. Moreover, efforts should be made to 
translating MRI research results (i.e. detection and monitoring of brain 
morphometric alteration and progression) into clinical practice to provide more 
reliable identification of patients individual-specific quantification of affected 
brain regions. 
Our future investigations will be associated with the ongoing longitudinal 
project related to our FEP patients group. Additionally, attempts are made to 
recruit a sample of long term schizophrenia patients and individuals with at 
genetic risk for psychosis/schizophrenia or any prodromal signs to investigate in 
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a comprehensive manner their cognitive functioning (dis-)similarities. Further-
more, disease related whole-body biomarker level alterations, particularly 
characteristics of inflammatory, oxidative stress and metabolism state as well as 
links between biomarker levels and cognitive functioning are of our interest.   
The real challenge for clinical psychiatry and neuroscience will be to use 
comprehensive advances in genetics, biochemistry, imaging and cognitive 
science in conjunction with symptom descriptions to provide a cognitive- and 
biomarkers based approach that would supplement the symptom-driven diag-
nostic process and help defining the therapeutic strategy for individual patient. 
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CONCLUSIONS 
This dissertation presents a comprehensive investigation into the cognitive im-
pairments among the FEP patients. The results suggest the following con-
clusions: 
 
1) FEP patients differed from healthy individuals in qualitative and quantitative 
aspects of their cognitive functioning, exhibiting widespread cognitive 
impairments. In particular, results indicated that although cognitive assess-
ments could be carried out in the same way in controls and patients, the 
nature of the relationships between observed test scores and their purported 
underlying constructs tended to be dissimilar. Higher inter-correlations of 
cognitive domains emerged for patients compared to control subjects. 
Patients’ cognitive profile tended to be more homogeneous. At the group 
level, patients demonstrated impairments in visual (i.e. pattern and spatial) 
recognition memory capacity, learning, set shifting, executive functioning, 
working memory (including storage and manipulation) as well as in the 
ability to rapidly process new information.   
 
2) There is variability in the type, direction, and size of the changes of different 
cognitive functions among FEP patients over time, and researchers, clini-
cians and neuropsychologists should consider measurement invariance, as 
well as patients’ demographic and clinical characteristics, when assessing 
neuropsychological change over time. Subjectively perceived and objecti-
vely measured cognitive deficits among FEP patients are two independent 
but likely complementary constructs, and should be measured separately in 
order to attain a more comprehensive assessment of each patient’s day-to-
day functioning.  
 
3) Morphological changes in the frontal, temporal, cingulate and parietal corti-
ces may be related to altered cognitive performance in FEP patients and that 
brain structure-function relationships may be dissimilar for FEP patients 
compared to CSs, when metrics of the CTh and CA – obtained by using MRI 
scanner – and cognitive performance – measured by the CANTAB tests  – 
are linked. 
In general, our findings acknowledge the need for continued efforts to inves-
tigate cognitive dysfunction and its underlying alterations in specific brain 
morphology as the biological feature of the early stage of schizophrenia.  
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SUMMARY IN ESTONIAN  
Esmase psühhoosiepisoodiga patsientide  
kognitiivne funktsionaalsus   
Psühhoos tähistab kliinilist sündroomi, mille puhul võivad ilmneda erinevad 
psühhopatoloogilised ilmingud: häired tajumises, mõtlemises, tunde- ja tahte-
elus, mis põhjustavad probleeme sotsiaalses toimimises. Psühhootilised häired 
on bioloogiliste põhjustega aju toimimise häired. Enamlevinud krooniline psüh-
hootiline häire on skisofreenia, mille puhul eelpoolnimetatud kliinilised tunnu-
sed indiviiditi ja haiguse erinevatel ajaperioodidel varieeruvad suurel määral. 
Üha suuremat kliinilist ja teadusuuringute põhist tähelepanu pööratakse häire 
esmasele psühhootilisele episoodile, mis avaldub enamasti noores täiskasvanu-
eas ja omab olulist prognostilist tähendust haigestunud isiku edasisele toime-
tulekule ühiskonnas.  
Alates XIX sajandi lõpust, mil Emil Kraepelin (Kraepelin, 1896) määratles 
skisofreenia dementia praecox’ina ehk enneaegse dementsusena, on häirele 
omase tuumsümptomina kirjeldatud ka patsientide kognitiivse funktsionaalsuse 
omapära.  
Kognitiivsed ehk tunnetusprotsessid tuginevad ajutasandi närvivõrgustiku 
toimimisele ning võimaldavad omandada uusi teadmisi, analüüsida informat-
siooni ning tagada ümbruses toimuvast arusaamise ja inimese toimimise teda 
ümbritsevas keskkonnas. Kognitiivsed ehk neuropsühholoogilised funktsioonid 
hõlmavad muuhulgas taju, mälu ja tähelepanu funktsioone, probleemilahendus-
oskuseid, infotöötluskiirust, otsustusvõimekust, keele ja varasemalt omandatud 
teadmiste kasutust.  
Kliiniliselt olulise kognitiivsete funktsioonide langusena käsitletakse olu-
korda, kus isiku sooritus ühe või enama testi põhiselt on taustagrupiga võrreldes 
üks või enam standardskoori madalam. Taustagrupi moodustavad enamasti 
terved eakaaslased, kes omavad uuritavatega sarnast haridustee pikkust. Skiso-
freeniahaigete grupis on leitud mitmete neuropsühholoogilisi funktsioone mõõt-
vate testide sooritamise raskuseid. Grupi tasandil ilmnevad neil haigetel (spet-
siifiliselt muude probleemsete haigusele omaste valdkondade hulgas) nt. töö-
mälu vähene maht, raskused kiires infotöötlemises, tähelepanu säilitamises/ 
ümberlülitumises ja uue info omandamises, probleemide lahendamises, järel-
duste tegemises ja tegevuse planeerimises ning olulise ja ebaolulise info 
eristamises. Teisalt, kuna antud häire puhul on tegemist väga erinevaid kogni-
tiivseid funktsioone hõlmavate probleemidega, on käsitlemist leidnud ka üldise 
ehk laiapõhjalise kognitiivse funktsioneerimisvõime häirumise vaatenurk 
(Dickinson et al. 2008).  
Kognitiivsete funktsioonide ebatõhusus mõjutab tugevalt haigete elukvali-
teeti ja sotsiaalset toimimist (Goldberg et al. 1993), mistõttu antud valdkonna 
uurimine on haiguse olemuse mõistmise ja ravistrateegiate planeerimise seisu-
kohalt väga oluline.  
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Uurimustöö eesmärgid:  
1) Iseloomustada esmase psühhootilise episoodiga patsientide kognitiivsete 
funktsioonide struktuuri, profiili ja sooritussuutlikkuse eripärasid võrreldes 
kontrollgruppi kuuluvate eakaaslastega, kasutades mõõtmisvahendina ala-
teste arvutipõhisest neuropsühholoogilisest testikogumikust Cambridge 
Neuropsychological Test Automated Battery (CANTAB).  
2) Hinnata esmasest psühhoosiepisoodist taastumise järgselt ehk kuue kuu 
möödudes patsientide kognitiivse funktsiooni struktuuri püsivust ajas ning 
sooritussuutlikkuse stabiilsust individuaalsel ja kogu grupi tasandil. Järg-
nevalt, uurida demograafiliste ja kliiniliste tegurite (vanus, sugu, haridustase, 
psühhopatoloogia raskusaste, antipsühhootilise ravimi annus) mõju sooritus-
suutlikkuse muutusele. Lisaks, võrrelda objektiivselt neuropsühholoogiliste 
testide abil mõõdetud ja patsientide subjektiivsete hinnangute kokkulange-
vust kognitiivsele sooritussuutlikkusele.   
3) Tuvastada aju funktsionaalse toimimise (hinnatuna CANTAB testipatareid 
kasutades) ja aju morfoloogiliste parameetrite (ajukoore paksuse ja ajukoore 
pindala – mõõdetuna magnetresonantsuuringut kasutades) vahelisi korrela-
tiivseid seoseid ning määratleda antud seoste erinevused esmase psühhoosi-
episoodiga patsientide grupis võrrelduna kontrollgruppi kuuluvate isikutega.  
 
Uuritavad ja meetodid  
Uurimistöö on läbi viidud Tartu Ülikooli Inimuuringute Eetikakomitee loa alu-
sel ning kõik uuritavad andsid kirjaliku informeeritud nõusoleku uuringus osale-
miseks. Uuritavateks olid valdavalt Sihtasutus Tartu Ülikooli Kliinikumi (SA 
TÜK) ja osaliselt Põhja-Eesti Regionaalhaigla psühhiaatriakliinikutesse krooni-
lise psühhootilise häire esmase psühhoosiepisoodi avaldumise järgselt ravile 
pöördunud patsiendid, vanuses 18–45 aastat ning terved, eakaaslastest vaba-
tahtlikud. Uuringus osales kokku 109 patsienti ja 96 kontrollgruppi kuuluvat 
isikut, kes valdasid eesti keelt ning kellel ei esinenud rasket kehalist haigust, aju 
orgaanilist haigust, vaimses arengus mahajäämust, väljendunud nägemis- ja 
kuulmislangust. Kontrollgruppi kuulumist välistas lisaks psühhootilise häire 
diagnoosi olemasolu lähisugulasel.   
Kognitiivsete funktsioonide objektiivseks hindamiseks kasutati arvutipro-
grammil põhinevat testipatareid CANTAB (Robbins & Sahakian 1994). Kasu-
tati alateste, mis võimaldasid hinnata uuritavate visuaalset ja ruumilist äratund-
mismälu, episoodilist mälu ja õppimisvõimet, tähelepanu ümberlülitumisvõi-
met, tegevuse planeerimis- ja täidesaatmisvõimekust, töömälu mahtu, töömälus 
oleva infoga toimetamisvõimekust ning infotöötluse kiirust. Antud alatestide 
tõhus sooritus toetub valdavalt närvivõrgustikele, mis hõlmavad eesajukoore, 
oimu- ja kiirusagara, vöökääru ning juttkeha vahelisi ühendusi. On täheldatud, 
et kroonilise psühhootilise häirega patsientide grupi tasandil ilmnevad raskused 
nimetatud testide teostamises ning see peegeldab häirele omast ulatuslikku 
kognitiivset düsfunktsionaalsust. 
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Patsientide psühhopatoloogia väljendusastme määratlemiseks oli kasutusel 
„Psühhiaatriline lühiskaala“ (Brief Psychiatric Rating Scale, BPRS) (Overall, 
1962).   
Subjektiivselt tajutud kognitiivset funktsionaalsust hinnati nelja enesekohase 
väite põhjal, mis pärinesid eesti keelde adapteeritud “Subjektiivse heaolu küsi-
mustiku” lühikesest versioonist (Subjective Well-Being under Neuroleptics-
Short Form (SWN-K, Naber et al., 2001) Estonian version (SWN-K-E, Haring 
et al. 2013).   
Ajukuvamisuuringud teostati SA TÜK radioloogiakliinikus, kasutades magnet-
resonantstomograafi ning tugeva magnetvälja abil saadud kujutisi ajukoore 
paksusest ja ajukoore pindalast. Vastavate parameetrite seoseid neuropsühho-
loogiliste testide tulemustega analüüsiti FreeSurfer v5.1.0 (http://surfer.nmr. 
mgh.harvard.edu) programmi abil. 
 
 
Uurimistöö peamised tulemused ja arutelu  
Uurimistöö esimeses etapis analüüsisime patsientide ja kontrollisikute gruppide 
tasanditel CANTAB alatestide skooride koondumiste eripärasid latentsete tun-
nuste koosseisu. Tunnuste grupeerimiseks kasutasime peakomponentide meeto-
dit ning ilmnenud konstruktide psühhomeetrilistele omadustele hinnangu and-
miseks kinnitavat faktoranalüüsi. Leidsime, et nii patsientide kui ka kontroll-
isikute grupis oli tunnuste koosvarieerumist võimalik teatavatele erinevustele 
vaatamata kirjeldada ühe- ja kahe-faktorilise mudeli abil. Edasise kinnitava 
faktoranalüüsi (hindamaks gruppide siseselt mõõdetud tunnuste kovariatsiooni-
maatriksite psühhomeetrilisi omadusi) viisime läbi ühe-faktorilise mudeli (kõik 
mõõdetud tunnused koondusid ühe latentse faktori ehk „Laiaulatusliku võime-
kuse faktori“ koosseisu) ning kahe-faktorilise mudeli (visuaalset-, ruumilist-, ja 
episoodilist mälu ning töömälus olevate infoühikute mahtu kajastavad tunnused 
koondusid „Tähelepanu/mälu faktori“ koosseisu ning töömälus oleva infoga 
manipuleerimist, tähelepanu ümberlülitumise ja tegevuse planeerimise efektiiv-
sust peegeldavad tunnused laadusid „Täidesaatva funktsiooni faktori“) alla. 
Tulemused kinnitasid, et CANTAB testide abil hinnatud kognitiivset funkt-
sionaalsust kirjeldavate tunnuste (testiskooride) kovariatsioonimaatriksite struk-
tuurid on mõlemas grupis defineeritavad ühe- ja kahe-faktorilise mudeli kaudu. 
Samas ilmnes oluline gruppide põhine erinevus kahe-faktorilise mudeli latent-
sete tunnuste vahelise korrelatsiooni tugevuses. Kontrollisikute grupis oli tähel-
datav teineteisest suhteliselt eristuvate faktorite („Tähelepanu/mälu faktori“ ja 
„Täidesaatva funktsiooni faktori“) profiil (korrelatsioon faktorite vahel r = 
0.31). Patsientide grupis antud latentsed faktorid omasid märkimisväärselt 
kõrgemat omavahelist korrelatsiooni suurust (r = 0.83). See viitas asjaolule, et 
patsientide grupis tugineb kognitiivsete funktsioonide realiseerumine oluliselt 
vähem modaalsusspetsiifilisele sooritusele ning pigem toetuvad patsiendid 
erinevat tüüpi soorituste puhul laiaulatusliku vaimse võimekuse faktori kaasa-
tusele. Teisisõnu viitab enam homogeenne kognitiivne profiil (kui sooritus oli 
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probleemsem ühe testi puhul, siis ilmnesid suure tõenäosusega raskused ka 
teiste alatestide teostamisel) patsientide grupis funktsionaalsuse ebaökonoom-
susele ning see võib peegeldada haigusega seonduvaid ja haigussümptomeid 
esile kutsuvaid protsesse. Meie tulemused on kooskõlas varasemate uuringutega 
(Leeson et al. 2009; Dickinson et al. 2008), mis samuti on näidanud kogni-
tiivsete funktsioonide suuremat koherentsust psühhoosihaigete grupis võrreldu-
na kontrollgruppi kuuluvate isikutega ning asjaolu, et patsientide grupi kogni-
tiivse funktsiooni kovariatsioonimaatriksi kirjeldamiseks sobib pigem ühe-
faktoriline („Laiaulatusliku võimekuse faktori“) mudel.  
Gruppide vaheline kinnitav faktoranalüüs võimaldas samaaegselt uurida 
kognitiivsete funktsioonide mõõtmistulemuste alusel loodud hüpoteetiliste 
faktor-struktuuride sobivust psühhootilise häirega isikute ja kontrollgrupis. 
Tegemist on mõõtmistulemuste struktuuri sarnasusele hinnangute andmisega 
erinevatel tasanditel.  
Kahe-faktorilise mudeli puhul leidsid kinnitust: gruppide vaheline faktor-
struktuuri ’konfiguraalne sarnasus’ (mõlemas grupis olid latentsed tunnused 
defineeritavad sarnaste algtunnuste poolt) ja ’nõrk struktuuri sarnasus’ (ilmnes 
faktorlaadungite sarnasus gruppides). Gruppide vaheline ’tugev struktuuri 
sarnasus’ eeldab, et nii faktorlaadungid kui ka indikaatortunnuste keskmised 
väärtused on mudelites sarnased. Meie tulemused näitasid, et antud tasemel 
eristusid mudelid teineteisest. See viitas asjaolule, et sarnased CANTAB ala-
testide skoorid defineerisid erinevates vaadeldud gruppides erinevaid latentseid 
tunnuseid. Kuna viimati nimetatud tasemel ilmnes mudelite faktorstruktuuri 
sarnasuse lahknevus, siis edasiste, enam piiranguid arvesse võtvate mudelite 
testimine ei olnud otstarbekas.   
Gruppide vahelise ühe-faktorilise mudeli struktuuri sarnasuse hindamisel 
leidis kinnitust üksnes ’konfiguraalne sarnasus’.  
Seega osutasid tulemused, et CANTAB testide mõõtmistulemuste kovariat-
sioonimaatriksite põhiselt loodud mudelite latentsete tunnuste skooride võrdlus 
ei ole asjakohane ning sooritussuutlikkusele hinnangu andmine gruppide tasan-
dil (psühhootilise häirega patsiendid võrreldes tervete kontrollisikutega) peaks 
toetuma alatestide põhjal saadud tulemustele.  
Lisaks ilmnes tulemuste põhjal, et enam iseloomustas patsientide kognitiivse 
kahjustuse profiili infotöötluskiiruse langus, raskus tegevuse planeerimisel ja 
täidesaatmisel, tähelepanu ümberlülitumisel ja töömälus oleva infoga toime-
tamisel. Patsientide grupis ilmnes tervete eakaaslastega võrreldes soorituse 
ebatõhusus ka visuaalse ja ruumilise äratundmise testide, episoodilise mälu ja 
õppimisvõime ülesande ning töömälu mahtu hindava testi osas. Antud tule-
mused kinnitasid varasemalt teostatud uuringuid (Gold & Harvey 1993; Hein-
richs & Zakzanis 1998), mille kohaselt juba kroonilise psühhootilise häire 
varajases staadiumis ilmneb patsientidel spetsiifiliste kognitiivsete funktsioo-
nide kahjustus, mis on oma olemuselt laiaulatuslik (Dickinson et al. 2008).     
Uurimistöö teises etapis analüüsisime patsientide grupis CANTAB testide 
põhiselt leitud kognitiivse sooritussuutlikkuse stabiilsust ajalises dünaamikas. 
Eristatakse kahte, teineteisest sõltumatut stabiilsust või ka muutuse ulatust kir-
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jeldavat tunnust: muutust individuaalses soorituses võrreldes teiste gruppi 
kuuluvate liikmetega ja grupi tasandil ilmnenud keskmise sooritussuutlikkuse 
muutust ajas. Tulemuste põhjal ilmnes kuuekuulise ajaintervalli järel langus 
ruumilise äratundmismälu ja episoodilise mälu/õppimisvõime testide skooride 
osas. Samas, tähelepanu ümberlülitumisvõime/vaimne paindlikkus, tegevusi 
täidesaatev funktsionaalsus, töömälus oleva infoga toimetamine ja informat-
siooni töötluskiirus ajas tõhustusid. Töömälu mahu ja visuaalse äratundmismälu 
osas muutuseid ei ilmnenud. Seega kinnitasid meie tulemused varasemaid 
uuringuid (Censits et al. 1997; Rund 1998; Heaton et al. 2001), mille kohaselt 
kroonilise psühhootilise häire varajases staadiumis ei esine laiaulatuslikku 
kognitiivse funktsionaalsuse langust.  
Lisaks säilitasid patsiendid kahel erineval testimiskorral saadud testiskooride 
põhiselt kõrge stabiilsuse grupi-siseses järjestuses (isikud, kes said kõrgemaid 
testiskoore algsel testimisel, said kõrgemaid skoore ka järgneval testimisel). 
Seega kaldusid kogu grupi tasandil saadud keskmiste testiskooride muutuste 
hinnangud iseloomustama enamikku patsientidest sarnasel viisil.  
Järgnevalt uurisime, kas kahe järjestikuse testimise käigus saadud testis-
kooride kovariatsioonimaatriksid esindavad sarnaseid struktuurimudeleid. Vara-
semalt näitasime, et patsientide grupi andmete puhul töötab paremini ühe-
faktoriline lahend. Kinnitav faktoranalüüs näitas, et sarnasus ajas antud faktor-
lahendi osas püsis ’konfiguraalsel’ ja ’nõrgal struktuuri sarnasuse’ tasemel. 
Tulemused pakkusid empiirilist tõendust hüpoteesile, et testiskoorid mõõtsid 
sarnast psühholoogilist tunnust ja latentsed faktorid omasid sarnast tähendust 
erinevatel ajahetkedel. Kuna aga edasistel faktorstruktuuri analüüsitasemetel 
sarnasus puudus, tuleks ka ajalises dünaamikas esmaste psühhoosihaigete grupis 
CANTAB testide skooridele/skooride muutustele hinnangute andmisel piirduda 
alatestide põhiselt saadud väärtustega.  
Edasine analüüs tõi esile, et võrreldes naispatsientidega osutus meeste 
sooritussuutlikkus tähelepanu ümberlülitusvõimet, eksekutiivset funktsionaal-
sust, töömälu mahtu ja töömälus oleva infoga manipuleerimisvõimekust hinda-
vate testide sooritamisel stabiilselt tõhusamaks. Meie tulemused kattusid osali-
selt varasemate tulemustega (Albus et al. 1997, Perlick et al. 1992, Roesch-Ely 
et al. 2009), kuid on ka viiteid vastupidistest tulemustest (Seidman et al. 1997; 
Goldstein et al. 1998) ning sooliste erinevuste puudumisest psühhoosihaigete 
valimi puhul (Hoff et al. 1998; Ittig et al. 2015).  
Tulemuste osas väärib tähelepanu asjaolu, et patsientide seisundi paranemine 
(hinnatuna psühhopatoloogiliste avalduste esinemismäära põhjal) jätkus peale 
haiglaravi, kuuekuulise jälgimisperioodi jooksul. Sümptomite taandumine ja 
kontrolli all püsimine võimaldas langetada antipsühhootilise raviannuse suurust, 
mis omakorda seondus tõhustunud eksekutiivse funktsionaalsuse ja suurenenud 
võimekusega hoida infot töömälus. Seetõttu oleks soovituslik ajalises dünaa-
mikas kliinilises töös kaaluda psühhopatoloogiliste avalduste taandumisega ja 
sümptomite kontrolli all püsimisega kooskõlaliselt antipsühhootilise raviannuse 
langetamise võimalust, mis grupi tasandilt vaadatuna võib soodustada kogni-
tiivset funktsioneerimisvõimekust.           
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Patsientide subjektiivselt tajutud hinnangud kognitiivsele funktsionaalsusele 
meie uuringus ei ühtinud objektiivselt, neuropsühholoogilise uuringu alusel 
saadud kognitiivse funktsionaalsuse hinnangutega. Ka varasemad uuringud 
(Zanello & Huguelet 2001, Stip et al. 2003) on tõdenud, et tegemist on kahe 
erineva konstruktiga, mis teineteist täiendavad.  
Kolmandas etapis keskendusime patsientide ja kontrollisikute aju morfo-
loogiliste parameetrite (ajukoore paksuse ja ajukoore pindala) ning kognitiivse 
funktsionaalsuse (töömälu mahu, töömälus oleva infoga manipuleerimisvõime, 
vaimse paindlikkuse, tegevuse planeerimise ja informatsiooni töötluskiiruse) 
korrelatiivsete seoste uurimisele. Meie tulemused kinnitasid varasemaid 
uuringutulemusi (Salgado-Pineda et al. 2003; Minatogawa-Chang et al. 2009; 
Gutiérrez-Galve et al. 2010; Crespo-Facorro et al. 2011), mille kohaselt difuus-
ne asümmeetriliselt väiksem ajukoore paksus ja ajukoore pindala (eeskätt ees-
aju, oimu-, kiirusagarate piirkonnas, vöökäärus) omasid korrelatiivseid seoseid 
vähese vaimse paindlikkuse ning madalama võimekusega toimetada töömälus 
oleva informatsiooniga ja strateegiate ebaefektiivsema kasutamisega töömälu 
ülesande sooritamisel. Lisaks, paksem vöökäär vasemal oli seotud tõhusama 
informatsioonitöötlusega ehk võimekusega eristada olulist informatsiooni eba-
oluliselt. Lisaks ilmnes seos ajukoore väiksema (kukla- ja oimusagara alade) 
pindala ja efektiivsema võimekusega hoida töömälus informatsiooniühikuid. 
Seostemustrid osaliselt haigete ja tervete isikute rühmades kattusid. Eelnevad 
uurijad (Toulopoulou et al. 2004; Cocchi et al. 2009; Minatogawa-Chang et al. 
2009; Crespo-Facorro et al. 2011; Ehrlich et al. 2012; Hatton et al. 2013) on 
näidanud, et esmase psühhootilise häirega patsientidele on omased teatavad aju 
struktuuride ja kognitiivse funktsionaalsuse seostemustrid. Ka meie uuring 
pakkus antud tõdemusele kinnitust. Psühhoosihaigete aju strukturaalseid ja 
funktsionaalsuse erisusi on seostatud aju arenguliste omapäradega (Weinberger 
1987; Murray & Lewis 1988) ja/või häirunud regeneratiivsete protsessidega 
(Falkai et al. 2015), mis omakorda seonduvad epigeneetiliste ja aju plastilisuse 
düsregulatsiooni mehhanismidega (Hasan et al. 2013). Lisaks toetab meie 
uurimus oletust, et psühhoosihaigete neuroanatoomilised/kognitiivse funktsio-
naalsuse eripärad ei seondu spetsiifiliste ajupiirkondadega, vaid pigem on 
haigusprotsessi ja/või haiguse kompensatoorsetesse mehhanismidesse kaasatud 
erinevad ajupiirkonnad.  
 
Antud uurimistöö läbiviimine on aidanud kaasa esmase psühhoosiepisoodiga 
patsientide kliinilise uurimise tõenduspõhise käsitluse juurdumisele SA TÜK 
psühhiaatriakliinikus.   
Meie edasiste uurimissuundade eesmärgid seonduvad esmase psühhoosiepi-
soodiga patsientide metabolismi, põletiku- ja oksüdatiivse stressi markerite eri-
pärade kaardistamisega ning biomarkerite ja kognitiivse funktsiooni seoste 
uurimisega. Lisaks on plaanis kaasata uuringusse haiguse kroonilises staadiumis 
olevaid patsiente ja psühhootilise häire suhtes riskigruppi kuuluvaid isikuid, et 
kirjeldada laiapõhjaliselt kroonilise psühhootilise häire erinevates faasides 
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ilmnevaid patofüsioloogilisi muutusi, mis võivad realiseeruda kliinilisel tasandil 
haigustunnustena ning mõjutada seeläbi patsientide igapäevast toimetulekut. 
 
Uurimistöö järeldused 
1) Uurimistöö tulemused viitasid, et võrreldes tervete eakaaslastega ilmneb 
esmase psühhoosiepisoodi järgselt patsientide grupi tasandil laiaulatuslik 
kvantitatiivne ja kvalitatiivne kognitiivne düsfunktsionaalsus. Probleemsed 
valdkonnad patsientide kognitiivsete funktsioonide sooritussuutlikkuses 
avaldusid: infotöötluskiirust, tegevuse planeerimist ja täidesaatmist, tähele-
panu ümberlülitumist ja töömälus oleva infoga toimetamisvõimekust ning 
visuaalse ja ruumilise äratundmismälu käepärasust, õppimisvõimekust ja 
töömälu mahtu hindavate testide läbimisel. Lisaks ilmnes, et sarnased 
CANTAB alatestide skoorid võisid defineerida erinevates vaadeldud grup-
pides sarnaseid latentseid tunnuseid, kuid mudelite aluseks olevad konst-
ruktid olid struktuurilt erinevad. Kahefaktorilise lahendi puhul avaldus 
patsientide grupis oluliselt kõrgem latentsete tunnuste omavaheline korrela-
tiivsus, mis peegeldas enam homogeense faktorstruktuuri olemasolu.  
2) Selgitasime, et patsientide grupis hinnatud kognitiivsete funktsioonide 
sooritussuutlikkuse muutused ajas võivad ilmneda määra, viisi ja suuna eri-
nevustes. Hinnates kliinilises töös või teadusuuringute kontekstis ajalises 
dünaamikas patsientide objektiivset kognitiivset funktsioneerimisvõimekust 
strukturaalsel ja sooritussuutlikkuse stabiilsuse tasandil, tuleks mõõtmis-
tulemuste kokkulangevustele hinnangute andmisel arvesse võtta patsientide 
demograafilisi ja kliinilisi eripärasid ning mõõtmisvahendi korduvast kasuta-
misest tulenevaid tegureid. Lisaks kinnitas uurimus, et patsientide poolt 
subjektiivselt tajutud kognitiivse kahjustuse määr ja objektiivselt neuro-
psühholoogiliste testide abil mõõdetud kognitiivne funktsionaalsus on eraldi-
seisvad konstruktid ning antud hinnangud pakuvad teineteisele täiendust, 
kirjeldamaks patsiendi igapäevast toimetulekuvõimekust.        
3) Tuvastasime, et morfoloogilised eripärad eesajukoores, oimu-, kiirusagarates 
ja vöökäärus omavad korrelatiivseid seoseid kognitiivse sooritussuutlik-
kusega. Lisaks kinnitasime, et esmase psühhoosiepisoodiga patsientide aju 
struktuuri (ajukoore paksus ja ajukoore pindala) ning funktsionaalsuse (mõõ-
detud CANTAB alatestide abil) korrelatiivsed seosed on erinevad tervete 
eakaaslastega võrreldes.    
 
Kokkuvõtvalt kinnitasid meie uuringutulemused, et kroonilise psühhootilise 
häire varajases staadiumis esineb patsientidel laiaulatuslik ja ajas suhteliselt 
püsiv kognitiivsete funktsioonide kahjustus, mis omab seoslikkust aju neuro-
bioloogiliste parameetritega.  
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APPENDIX 
Tables A1  ̶A3.  
 
Table A1. Results of the between-group (first-episode psychotic (FEP) patients (n = 63) 
compared to control subjects (CSs) (n = 30)) differences within cortical thickness (CTh) 
and surface area (CA). Only statistically significant differences in CTh and CA clusters 
(may span more than one anatomical region), clusters sizes, and corresponding anatomi-
cal region names are reported. Standard FreeSurfer atlases were used to determine 
anatomical nomenclature. 
  Cluster Brain region Size Pcw* 
Pcw  
Low to 
High 
FEP 
patients 
Mean 
(S.D.)  
 
CSs  
Mean 
(S.D.) 
Thickness LH 
Superior 
frontal  1283 0.0019 
0.0014  ̶
0.0025 
3.02 
(0.23) 
3.22 
(0.18) 
 
 
 
Caudal anterior 
cingulate      
Superior 
frontal  1193 0.0039 
0.0031  ̶
0.0047 
2.59 
(0.21) 
2.77 
(0.19) 
 
Rostral 
middlefrontal      
Temporal pole  1051 0.0093 
0.0081  ̶
0.0011 
3.44 
(0.34) 
3.14 
(0.39) 
 
Fusiform 
   
  
Entorhinal 
Superior 
temporal 
Insula 
RH 
Rostral 
middlefrontal  5158 0.0001 0 – 0.0002 
2.81 
(0.19) 
3.01 
(0.22) 
 
 
Caudal 
middlefontal 
   
  
Superior 
frontal 
Precentral  1371 0.0012 
0.0008 – 
0.0017 
2.53 
(0.26) 
2.30 
(0.42) 
Middle 
temporal  1107 0.0084 
0.0072 – 
0.0096 
3.03 
(0.26) 
2.73 
(0.38) 
 
Inferior 
temporal    
 
 
Area LH 
Rostral 
middlefrontal  1055 0.0095 
0.0083 – 
0.0108 
1.04 
(0.10) 
0.94 
(0.11) 
 
  
Pars 
triangularis    
 
 
RH 
Lateral 
occipital  2359 0.0001 0 – 0.00002
0.92 
(0.08) 
0.85 
(0.07) 
  
Inferior 
parietal 
   
  
Superior 
parietal 
 
*The p-values are expressed as cluster-wise probability (Pcw ), and Pcw is equivalent to the overall alpha 
significance level. LH – left hemisphere; RH – right hemisphere. Surface area is expressed in mm2, cortical 
thickness is expressed in mm. All comparisons were made controlling for the effects of age and gender.  
Significance was set at p < 0.05 (FDR corrected). 
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Table A2. Cortical grey matter thickness and area correlations with neurocognitive 
performance in FEP patients (n = 63) and CS group (n = 30). Standard FreeSurfer 
atlases were used to determine anatomical nomenclature. 
FEP patients 
  Cluster Brain region Size Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
IED        
Thickness LH Fusiform  2932 0.0001 0 – 0.0002 2.23 (0.14) 
 
 
 
Inferior temporal 
    
Lateral occipital 
Lingual 
Pericalcarine 
Cuneus 
Precuneus 
Superior frontal  2919 0.0001 0 – 0.0002 2.97 (0.21) 
 
Lateral orbitofrontal 
    
Medial orbitofrontal 
Rostral anterior 
cingulate 
Caudal anterior 
cingulate 
Isthmus cinguli  2330 0.0001 0 – 0.0002 2.72 (0.16) 
 
Precuneus 
    
Lingual 
Posterior cingulate 
Paracentral 
Superior frontal 
Caudal anterior 
cingulate 
Rostral 
middlefrontal  2778 0.0001 0 – 0.0002 2.65 (0.18) 
 
Pars opercularis 
    
Pars triangularis 
Precentral 
RH Superior frontal  6649 0.0001 0 – 0.0002 2.97 (0.21) 
 
 
Medial orbitofrontal 
    
Rostral middlefrontal 
Pars triangularis 
Pars opercularis 
Precentral 
Caudal  middlefrontal
Posterior 
cingulate  3470 0.0001 0  ̶ 0.0002 2.54 (0.16) 
 
Paracentral 
    
Superior frontal 
Isthmus cingulate 
Lingual 
Parahippocampal 
Cuneus 
Pericalcarine 
Precuneus 
Superior parietal 
Area LH
Pars  
triangularis  1038 0.0088 
0.0076 – 
0.01 1.09 (0.11) 
 
  
Pars orbitalis 
    Rostral middlefrontal 
RH No      
89 
FEP patients 
  Cluster Brain region Size Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
SOC        
Thickness LH No       
 RH No       
Area LH No       
 RH No       
SSP        
Thickness LH No       
 RH No       
Area LH No       
 
RH Lingual  1133 0.007 
0.0059 – 
0.0081 0.88 (0.09) 
  
Pericalcarine 
    
Lateral occipital 
Fusiform 
Lateral occipital 
SWM 
strategy        
Thickness LH
Rostral 
middlefrontal   8658 0.0001 0 – 0.0002 2.79 (0.19) 
 
 
 
Caudal middlefrontal 
    
Superior frontal 
Posterior cingulate 
Caudal anterior 
cingulate 
Medial orbitofrontal 
Rostral anterior 
cingulate 
Lateral orbitofrontal 
Pars opercularis   1836 0.0015 
0.001 – 
0.002 2.90 (0.16) 
 
Pars triangularis 
    
Insula 
Precentral 
Postcentral 
Inferior parietal  1777 0.0021 
0.0015 – 
0.0027 2.49 (0.20) 
 Supramarginal     Superior parietal 
Fusiform   1533 0.0079 
0.0068 – 
0.009 2.32 (0.16) 
 
Lingual 
    Lateral occipital 
RH
Rostral 
middlefrontal   10520 0.0001 0 – 0.0002 2.76 (0.16) 
 
 
Caudal middlefrontal 
    
Precentral 
Pars opercularis 
Pars triangularis 
Medial orbitofrontal 
Superior frontal 
Rostral middlefrontal 
Precuneus  4146 0.0001 0 – 0.0002 2.54 (0.15) 
 
Parahippocamapal 
    Lingual 
90 
FEP patients 
  Cluster Brain region Size Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
Isthmus cingulate 
Posterior cingulate 
Superior frontal 
Inferior parietal   2800 0.0001 0 – 0.0002 2.61 (0.16) 
 
Supramarginal 
    
Superior temporal 
Inferior parietal 
Area LH
Superior  
frontal  1890 0.0001 0 – 0.0002 1.12 (0.09) 
 
 
 
Rostral middlefrontal 
    
Frontal pole 
Lateral orbitofrontal 
Pars triangularis 
Temporal pole  1780 0.0001 0 – 0.0002 1.31 (0.13) 
 
Inferior temporal 
    
Fusiform 
Superior temporal 
Middle temporal 
RH
Superior  
temporal  2274 0.0001 0 – 0.0002 1.20 (0.11) 
  
Middle temporal 
    
Inferior temporal 
Fusiform 
Entorhinal 
SWM 
errors        
Thikness LH Superior frontal   15140 0.0001 0 – 0.0002 0.94 (0.05) 
 
 
 
Caudal anterior 
cingulate 
    
Paracentral 
Rostral anterior 
cingulate 
Medial orbitofrontal 
Rostral middlefrontal 
Lateral orbitofrontal 
Caudal middlefrontal 
Pars orbitalis 
Pars triangularis 
Insula 
Precentral 
Fusiform  1955 0.0007 
0.0004 – 
0.001 0.88 (0.05) 
 
Lingual 
    Lateral occipital 
Pericalcarine  1952 0.0007 
0.0004 – 
0.001 0.90 (0.06) 
 
Precuneus 
    
Superior parietal 
Cuneus 
RH Precentral  15953 0.0001 0 – 0.0002 0.91 (0.04) 
  
Superior frontal 
    
Caudal middlefrontal 
Rostral middlefrontal 
 Pars opercularis 
Pars trinagularis 
91 
FEP patients 
  Cluster Brain region Size Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
Postcentral 
Supramarginal 
Inferior parietal 
Middle temporal 
Medial orbitofrontal 
Caudal anterior 
cingulate 
Precuneus  3595 0.0001 0 – 0.0002 0.87 (0.03) 
 
Isthmus cingulate 
    
Posterior cingulate 
Lingual 
Paracentral 
Area LH Inferior temporal  1356 0.0014 
0.0009 – 
0.0019 1.12 (0.10) 
 
 
 
Middle temporal 
    
Temporal pole 
Superior temporal 
Pars orbitalis  1290 0.0019 
0.0014 – 
0.0025 1.10 (0.11) 
 
Lateral orbitofrontal 
    
Pars triangularis 
Rostral middlefrontal 
RH
Superior 
temporal  1724 0.0002 0 – 0.0004 1.07 (0.09) 
 
 
Middletemporal 
    
Inferior temporal 
Temporal pole 
Medial 
orbitofrontal  1128 0.0073 
0.0062 – 
0.0084 1.30 (0.13) 
 
Superior orbital 
    Rostral middlefrontal 
RVP        
Thickness LH Superior frontal  1840 0.0018 
0.0013 – 
0.0024 2.87 (0.21) 
 
  
Posterior cingulate 
    
Caudal anterior 
cingulate 
Rostral anterior 
cingulate 
RH No       
Area LH No       
 RH No       
 
 
 
 
 
CSs 
  Cluster Brain region Size  
 
Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
IED        
Thickness LH No      
 RH No      
Area LH No      
 RH No      
92 
CSs 
  Cluster Brain region Size  
 
Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
SOC        
Thickness LH 
Middle 
temporal  3409 0.001 
 
0 – 0.002 
2.51 
(0.22) 
 
 
 Inferior temporal 
    
Fusiform 
Lingual 
Pericalcarine 
Cuneus 
RH 
Temporal 
pole  1893 0.001 0.001 – 0.002 
2.97 
(0.35) 
 
 
Entorhinal 
    
Inferior temporal 
Fusiform 
Parahippocampal 
Middle temporal 
Superior 
temporal  1724 0.0033 
0.0026 – 
0.004 
2.83 
(0.23) 
 
Insula 
  
 
 
Transverse temporal 
Middle temporal 
Area LH No      
 RH No      
SSP        
Thickness LH No      
 RH No      
Area LH No      
 
RH Pericalcarine  1341 0.0015 0.001 – 0.002 
0.88 
(0.17) 
  
Cuneus 
  
 
 Lingual 
SWM 
strategy  
     
 
Thickness LH 
Lateral 
orbitofrontal  2260 0.0001 
 
0 – 0.0002 
2.88 
(0.22) 
 
  
Pars opercularis 
  
 
 
Pars triangularis 
Insula 
RH 
Pars 
triangularis  1787 0.0043 
0.0035 – 
0.0051 
2.78 
(0.22) 
 
 
Rostral 
middlefrontal 
    Pars orbitalis 
Fusiform  1988 0.0023 
0.0017 – 
0.0029 
2.51 
(0.21) 
 
Lingual 
    
Lateral occipital 
Inferior temporal 
Middle temporal 
Precentral  1777 0.0045 
0.0037 – 
0.0054 
2.53 
(0.40) 
 
Paracentral 
    Superior frontal 
Precuneus  1938 0.0026 
0.002 – 
0.0033 
2.58 
(0.26) 
 Cuneus     
93 
CSs 
  Cluster Brain region Size  
 
Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
Pericalcarine 
Superior parietal 
Isthmus cingulate 
Posterior cingulate 
Area LH No      
 RH No      
SWM 
errors      
 
 
Thikness LH 
Superior 
frontal  1765 0.0023 
0.0023 – 
0.0029 
2.56 
(0.29) 
 
 
 
Precentral 
   
 
 Paracentral 
Precentral  7153 0.0001 0 – 0.0002 
2.69 
(0.20) 
 
Lateral orbitofrontal  
    
Caudal 
middlefrontal 
Insula 
Pars opercularis 
Pars triangularis 
Rostral 
middlefrontal 
Postcentral 
Precuneus  3565 0.0001 0 – 0.0002 
2.41 
(0.20) 
 
Isthmus cingulate 
    
Cuneus 
Pericalcarine 
Superior parietal 
Inferior parietal 
RH Precentral  4018 0.0001 0 – 0.0002 
2.57 
(0.33) 
 
 
Superiorfrontal 
    
Caudal 
middlefrontal 
Paracentral 
Fusiform  1980 0.0012 
0.0008 – 
0.0017 
2.36 
(0.18) 
 
Lateral occipital 
    Lingual 
Precuneus  3977 0.0001 
0.0001 – 
0.0002 
2.49 
(0.23) 
 
Isthmus cingulate 
    
Posterior cingulate 
Cuneus 
Pericalcarine 
Superior parietal 
Lateral 
occipital  2971 0.0001 0 – 0.0002 
2.53 
(0.23) 
 
Inferior parietal 
    Superior parietal 
Pars 
triangularis 
 
2927 0.0001 0 – 0.0002 
2.76 
(0.21) 
 
Pars opercularis 
    Pars orbitalis 
94 
CSs 
  Cluster Brain region Size  
 
Pcw* 
Pcw  
Low to High 
Mean 
(S.D.) 
Rostral 
middlefrontal 
Lateral orbitofrontal 
Superior 
temporal 
 
2726 0.0001 0 – 0.0002 
2.91 
(0.25) 
 
Fusiform 
    
Inferior temporal 
Middletemporal 
Banks of the 
superior temporal 
sulcus 
Inferior parietal 
Supramarginal 
Area LH Precentral  2250 0.0001 0 – 0. 0002 
0.88 
(0.09) 
 
 
 
Superior frontal 
    
Caudal 
middlefrontal 
Rostral 
middlefrontal 
Precuneus  1167 0.0037 
0.0029 – 
0.0045 
1.00 
(0.10) 
 Superior parietal     
RH 
Pars 
triangularis 
 
2029 0.0001 
 
0.0001 – 
0.0002 
1.04 
(0.08) 
 
 
Precentral 
  
 
 
Pars opercularis 
Pars orbitalis 
Insula 
Lateral orbitofrontal 
Rostral 
middlefrontal 
 
1389 0.0009 
 
0.0005 – 
0.0013 
1.07 
(0.10) 
 Superior frontal    
 Medial orbitofrontal 
RVP        
Thickness LH No      
 RH No      
Area LH No      
 RH No      
 
*The p-values are expressed as cluster-wise probability (Pcw) and Pcw is equivalent to the overall alpha 
significance level. LH – left hemisphere, RH – right hemisphere.  
Surface area is expressed in mm2, cortical thickness is expressed in mm. 
IED – intra/extradimensional shift; SOC – Stockings of Cambridge; SSP – spatial span; SWM error and 
strategy – spatial working memory errors and strategy scores; RVP – rapid visual information processing.  
All comparisons were made controlling for the effects of age and gender.  
Significance was set at p < 0.05 (FDR corrected).  
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Table A3. Significant relationship differences between cortical thickness/area and 
neuropsychological measures between the FEP patients (n = 63) and control subjects  
(n = 30). Standard FreeSurfer atlases were used to determine anatomical nomenclature. 
  Cluster Brain region Size  Pcw* 
Pcw  
Low to High 
IED       
Thickness LH No     
 RH No     
Area LH Pars triagularis  964 0.0015 0.001 – 0.002 
   Pars orbitalis    
Rostral middlefrontal 
RH No     
SOC       
Thickness LH Entorhinal  1546 0.0001 0 – 0.0002 
   Inferior temporal    
Fusiform 
Lingual 
RH Middle 
temporal 
 1709 0.0001 0 – 0.0002 
  Superior temporal    
Transverse temporal 
Insula 
Temporal pole  1434 0.0008 0.0005 – 0.0012 
 Inferior temporal    
Middle temporal 
Entorhinal 
Fusiform 
Inferior parietal  1278 0.0026 0.002 – 0.0033 
 Middle temporal    
Area LH No  
 RH Lateral 
occipital 
 1106 0.0003 0.0001 – 0.0005 
  Cuneus    
Pericalcarine 
Lingual 
SSP       
Thickness LH No     
 RH No     
Area LH No     
 RH No     
SWM 
strategy 
      
Thickness LH No     
 RH Supramarginal  1196 0.0047 0.0038 – 0.0056 
  Superior temporal    
Inferior parietal 
Area LH No     
 RH No     
SWM errors       
Thickness LH No     
 RH Paracentral  1959 0.0001 0 – 0.0002 
  Precntral    
Postcentral 
96 
  Cluster Brain region Size  Pcw* 
Pcw  
Low to High 
Area LH No     
 RH No     
RVP       
Thickness LH No     
 RH Lingual  1297 0.0024 0.0018 – 0.003 
  Fusiform    
Lateral occipital 
Cuneus 
Pericalcarine 
Area LH No     
 RH No     
 
*The p-values are expressed as cluster-wise probability (Pcw), and Pcw is equivalent to the overall alpha 
significance level. LH – left hemisphere, RH – right hemisphere.  
Surface area is expressed in mm2, cortical thickness is expressed in mm. 
IED  ̶ intra/extradimensional shift; SOC – Stockings of Cambridge; SSP – spatial span; SWM error and 
strategy – spatial working memory errors and strategy scores; RVP – rapid visual information processing.  
All comparisons were made controlling for the effects of age and gender.  
Significance was set at p < 0.05 (FDR corrected). 
 
Note: Paper III comprises Supplementary materials in relation to MRI results 
(i.e. statistical maps of cortical parameters and their associations with cognitive 
functioning as well as descriptions of particular clusters, corresponding 
anatomical region names, cluster sizes, and statistical significance values). The 
same information is provided in the dissertation under the Figure 6 – 9 and in 
the Table A1 – A3, and is not added extra to the manuscript.  
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